

Curriculum Vitae

Adam J. Olszewski, MD

Associate Professor of Medicine, Alpert Medical School of Brown University

Address: Brown University Health / Rhode Island Hospital
George Building, Rm. 353
593 Eddy St, Providence, RI 02903
Tel: (844) 222 2881
Fax: (401) 444 8918
E-mail: adam_olszewski@brown.edu
 ORCID [0000-0002-6472-6658](https://orcid.org/0000-0002-6472-6658)

Language fluency: Spanish, French, Polish, Russian
Research profile: <https://vivo.brown.edu/display/aolszews>

Employment

Rhode Island Hospital / Lifespan Cancer Institute Clinical Hematologist/Oncologist and researcher	02/2016 – present
Alpert Medical School of Brown University - Associate Professor of Medicine - Assistant Professor of Medicine	08/2019 – 08/2010 – 07/2019
Memorial Hospital of Rhode Island - Clinical Oncologist / Hematologist - Cancer Committee Chair	08/2010 – 02/2016
Kent County Hospital, Warwick, RI - Clinical Oncologist / Hematologist - Physician Director, Outpatient Infusion Services	2007 – 2010
University Medical Group, Providence, RI Clinical Oncologist / Hematologist	2006 – 2010

Education

Hematology/Oncology Fellowship St. Luke's-Roosevelt Hospital Center, New York	07/2003 – 06/2006
Internal Medicine Residency St. Luke's-Roosevelt Hospital Center, New York Teaching affiliate of College of Physicians and Surgeons of Columbia University	07/2000 – 06/2003
The Medical University of Warsaw, Poland MD degree 06/1999	09/1993 – 06/1999

Licensure and certification

ABIM Board Certified: Hematology	11/2007 – present
ABIM Board Certified: Medical Oncology	11/2006 – present
ABIM Board Certified: Internal Medicine	08/2003 – present
MD License: Rhode Island	11/2005 – active

Research support

Current

Leukemia & Lymphoma Society (Clinical Research Scholar) Olszewski (PI) 4/2022-3/2027
Mosunetuzumab with lenalidomide augmentation as first-line therapy for patients with follicular and marginal zone lymphoma

F. Hoffmann-La Roche Ltd / Genentech, Inc. (Clinical trial, NCT04792502) Olszewski (PI) 4/2021-3/2026
BrUOG 401: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

BPI Inc. Academic Assessment Research grant Olszewski (PI) 10/2023-9/2024
Immune cell exhaustion during bispecific antibody therapy for B-cell lymphoma: a correlative study

NIH (1P30GM145500) Quesenberry (PI) 07/2023-06/2028
COBRE for Stem Cells and Aging (SCA)

NIGMS (U54GM115677, Advance-CTR Pilot Award) Pelcovits (PI)/Olszewski (mentor) 10/2023-09/2024
The tumor microenvironment and response to immunotherapies in follicular and marginal zone lymphoma

Completed

NIGMS (U54GM115677, Advance-CTR Pilot Award) Kurt (PI)/Olszewski (mentor) 09/2022-10/2023
Identification of unique epigenetic signatures predicting response to hypomethylating agents in myelodysplastic syndrome

Spectrum Pharmaceuticals, Inc. (IIS-MAR-003) Olszewski (PI) 1/2017-12/2020
A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with Bendamustine and Rituximab (BRiM) in Indolent non-Hodgkin Lymphoma

Adaptive Biotechnologies (in-kind research support) Olszewski (PI) 12/2018-12/2020
Cerebrospinal fluid analysis of clonotypic cfDNA as a diagnostic and prognostic marker of CNS invasion in aggressive lymphoma

NIGMS (U54GM115677, Advance-CTR Pilot Award) Olszewski (PI) 7/2017-10/2018
Clonal hematopoiesis in recipients of myelotoxic therapy for solid tumors

American Cancer Society (Research Scholar Award) Olszewski (PI) 3/2016-8/2019
Access to oral chemotherapy and survival outcomes in multiple myeloma

ASH Research Scholar Award (Career Development Award) Olszewski (PI) 7/2015-6/2017
The impact of novel therapies on clinical outcomes and resource utilization in older Americans with Waldenström's macroglobulinemia

Rhode Island Foundation Medical Research Grant Olszewski (PI) 5/2015-6/2016
Skeletal-related events in Medicare beneficiaries with chronic lymphocytic leukemia

Clinical trials

Schrodinger, Inc. (Clinical trial, NCT05544019)
Olszewski (Local PI) 02/2023-...
Study of SGR-1505 in Mature B-Cell Neoplasms

Artiva Biotherapeutics, Inc. (Clinical trial, NCT04673617)
Olszewski (Local PI) 08/2023-...
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Pfizer (Clinical trial, NCT05626322)

Olszewski (Local PI) 11/2023-...
Effects of Maplirpacept (PF-07901801), Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Kymera Therapeutics, Inc. (Clinical trial, NCT05225584)
Olszewski (Local PI) 07/2023-...
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

F. Hoffmann-La Roche Ltd / Genentech, Inc. (Clinical trial, NCT03677141)
Olszewski (Local PI) 2/2019-...
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

F. Hoffmann-La Roche Ltd / Genentech, Inc. (Clinical trial, NCT03671018)
Olszewski (Local PI) 5/2019-...
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

F. Hoffmann-La Roche Ltd / Genentech, Inc. (Clinical trial, NCT03677154)
Olszewski (Local PI) 5/2019-...
A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy

Genmab (Clinical trial, NCT03625037)
Olszewski (Local PI) 8/2020-...
GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Precision BioSciences, Inc. (Clinical trial, NCT03666000)
Olszewski (Local PI) 12/2020-...
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

Precision BioSciences, Inc. (Clinical trial, NCT04649112)
Olszewski (Local PI) 07/2022-10/2023
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

TG Therapeutics, Inc. (Clinical trial, NCT02793583)
Olszewski (Local PI) 5/2018-...
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin s Lymphoma

Spectrum Pharmaceuticals, Inc. (Clinical trial, completed, NCT02257242)
Olszewski (PI) 1/2017-12/2020
A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with Bendamustine and Rituximab (BRiM) in Indolent non-Hodgkin Lymphoma

Celldex Therapeutics (Clinical trial, NCT03329950)
Olszewski (Local PI) 4/2020-3/2022
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

F. Hoffmann-La Roche Ltd / Genentech, Inc. (Clinical trial, completed, NCT02431208)

Olszewski (Local PI)

9/2018-2/2019

LS-P-PAMM: A Phase 1B study of the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) alone or in combination with an immunomodulatory drug and/or daratumumab in patients with multiple myeloma (relapsed/refractory and post-autologous stem cell transplantation)

F. Hoffmann-La Roche Ltd / Genentech, Inc.

(Clinical trial, completed, NCT02624986)

Olszewski (Local PI)

11/2016-8/2018

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Peer-reviewed publications (reverse chronological order)

h index: 33

PubMed bibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/adam.olszewski.1/bibliography/40055989/public/>

1. **Olszewski AJ**, Treaba DO, Winter A, Donnelly S, Ollila TA. Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma. *British journal of haematology*. 2025. Epub 20250921. doi: 10.1111/bjh.70178. PubMed PMID: 40976986.
2. Bonal DM, Oakes A, Chorzalska A, Pardo M, Petersen M, Clarke MY, Lee SH, **Olszewski AJ**, Treaba DO, Reagan JL, Dooner MS, Morgan J, Bertone P, Zhao T, Yang W, Ventetuolo CE, Hobbs GS, Mills J, Dubielecka PM. HiJAKing the Hematopoietic System: A Low-Frequency JAK2V617F Clone Drives Myeloproliferative Neoplasm Pathology. *Blood*. 2025. Epub 20250725. doi: 10.1182/blood.2024027125. PubMed PMID: 40729727.
3. Epperla N, **Olszewski AJ**, Ayers EC, Ahmed S. Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Hematological oncology*. 2025;43(5):e70128. doi: 10.1002/hon.70128. PubMed PMID: 40836271; PMCID: PMC12368254.
4. Epperla N, Shouse G, Grover NS, Torka P, Annunzio K, Watkins M, Anampa-Guzman A, Christian B, Thomas C, Barta SK, Geethakumari PR, Karmali R, Bartlett NL, **Olszewski AJ**. Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study. *Exp Hematol Oncol*. 2025;14(1):73. Epub 20250514. doi: 10.1186/s40164-025-00666-z. PubMed PMID: 40369604; PMCID: PMC12079943.
5. Ghosh N, Bellasea S, Li H, **Olszewski AJ**, Bryan L, Danilov A, Smith S, LeBlanc M, Friedberg JW. SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low-Tumor Burden Follicular Lymphoma. *JCO Oncol Adv*. 2025;2(1):e2500037. Epub 20250417. doi: 10.1200/OA-25-00037. PubMed PMID: 40264918; PMCID: PMC12011429.
6. Torka P, Grover NS, Voorhees TJ, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmán A, Reyes H, Tavakkoli M, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, **Olszewski AJ**, Epperla N. Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study. *Hematological oncology*. 2025;43(3):e70087. doi: 10.1002/hon.70087. PubMed PMID: 40260947; PMCID: PMC12013245.
7. Milrod CJ, Rubin L, Martinez B, Ollila TA, **Olszewski AJ**, Pelcovits A. Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review. *Lancet Haematol*. 2025;12(4):e312-e7. doi: 10.1016/S2352-3026(25)00032-8. PubMed PMID: 40175003.
8. Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, **Olszewski AJ**, Arnason JE, Ahn IE, Brown JR. Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease. *J Clin Oncol*. 2025;43(7):788-99. Epub 20241207. doi: 10.1200/JCO-24-02503. PubMed PMID: 39645236.
9. Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzman A, Oh TS, Reyes H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, **Olszewski AJ**, Epperla N. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. *Blood Cancer J*. 2024;14(1):182. Epub 20241018. doi: 10.1038/s41408-024-01162-z. PubMed PMID: 39424808; PMCID: PMC11489653.
10. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein PG, Chaudhry A, **Olszewski AJ**. High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. *Blood Adv*. 2024. Epub 20240827. doi: 10.1182/bloodadvances.2024013791. PubMed PMID: 39189932.

11. **Olszewski AJ**. When B cells rebuff bispecifics. *Blood*. 2024;143(9):744-6. doi: 10.1182/blood.2023023312. PubMed PMID: 38421818.
12. Budde LE, **Olszewski AJ**, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. *Nat Med*. 2024;30(1):229-39. Epub 20231210. doi: 10.1038/s41591-023-02726-5. PubMed PMID: 38072960; PMCID: PMC10803244.
13. Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, **Olszewski AJ**, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. *Blood Adv*. 2024;8(13):3507-18. Epub 20240513. doi: 10.1182/bloodadvances.2024012800. PubMed PMID: 38739715; PMCID: PMC11261035.
14. Milrod CJ, Kim KW, Raker C, Ollila TA, **Olszewski AJ**, Pelcovits A. Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis. *Br J Haematol*. 2024 Apr 4. doi: 10.1111/bjh.19449. PMID: 38571449
15. Mirza FN, **Olszewski AJ**, Pelcovits AR, DiMarco C, Firoz EF. Sezary syndrome associated vitiligo-like leukoderma in type V skin: Report of a case and review of the literature. *JAAD Case Rep*. 2024;48:103-7. Epub 20240415. doi: 10.1016/j.jidcr.2024.04.009. PubMed PMID: 38813064; PMCID: PMC11134528.
16. Baird CE, Wulff-Burchfield E, Egan PC, Hugar LA, Vyas A, Trikalinos NA, Liu MA, Bélanger E, **Olszewski AJ**, Bantis LE, Panagiotou OA. Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study. *J Geriatr Oncol*. 2024 Apr 26;15(5):101774. doi: 10.1016/j.jgo.2024.101774. PMID: 38676975
17. Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, **Olszewski AJ**, Bartlett NL. Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. *Blood Adv*. 2024;8(3):549-52. Epub 20231213. doi: 10.1182/bloodadvances.2023011698. PubMed PMID: 38091577; PMCID: PMC10835265.
18. **Olszewski AJ**, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin JR, Lossos IS, Munoz J, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. *Blood Adv*. 2023. Epub 20230815. doi: 10.1182/bloodadvances.2023010840. PubMed PMID: 37581593.
19. Pelcovits A, Ollila TA, **Olszewski AJ**. Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma. *Cancer Manag Res*. 2023;15:989-98. Epub 20230906. doi: 10.2147/CMAR.S330908. PubMed PMID: 37700809; PMCID: PMC10493109.
20. Ollila TA, Taher R, Moku P, **Olszewski AJ**. Immunochemotherapy or Chemotherapy Alone in Primary Central Nervous System Lymphoma, a National Cancer Data Base Analysis. *Blood Adv*. 2023. Epub 20230717. doi: 10.1182/bloodadvances.2023010352. PubMed PMID: 37459209.
21. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzman A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, **Olszewski AJ**, Epperla N. Impact of circulating lymphoma cells at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. *Blood Adv*. 2023 Nov 28;7(22):6839-6843. doi: 10.1182/bloodadvances.2023011288. PubMed PMID: 37792806.
22. Farooq F, Brandt JS, Cardonick E, Polushkina E, Vose JM, Ahmed S, Ramakrishnan Geethakumari P, **Olszewski AJ**, Yasin H, Farooq U, Hamad N, Lin Y, Maggen C, Fruscio R, Gziri MM, Steffensen KD, Amant F, Evens AM. An International Real-World Analysis of Relapsed/Refractory Lymphoma Occurring During Pregnancy. *Blood Adv*. 2023. Epub 20230601. doi: 10.1182/bloodadvances.2023010090. PubMed PMID: 37259563.
23. Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, **Olszewski AJ**. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. *Blood Adv*. 2023;7(17):5038-46. doi: 10.1182/bloodadvances.2023010133. PubMed PMID: 37315169.
24. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girtan MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos BM, Karmali R, Oh TS, Vose JM, Nutsch HR, Rubinstein PG, Chaudhry A, **Olszewski AJ**. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. *Blood Adv*. 2023. Epub 20230512. doi: 10.1182/bloodadvances.2023009731. PubMed PMID: 37171397.

25. McKenna M, Epperla N, Ghobadi A, Liu J, Lazaryan A, Ibrahim U, Jacobson CA, Naik SG, Nastoupil L, Chowdhury SM, Voorhees TJ, Jacobs MT, Farooq U, Osman K, **Olszewski AJ**, Ahmed S, Evens AM. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. *Br J Haematol*. 2023. Epub 20230502. doi: 10.1111/bjh.18828. PubMed PMID: 37129856.
26. Bakow BR, Phung Q, Rabinovich D, **Olszewski AJ**, Reagan JL. Choice of anticoagulation in patients with low risk antiphospholipid syndrome. *J Thromb Thrombolysis*. 2023. Epub 20230523. doi: 10.1007/s11239-023-02826-6. PubMed PMID: 37219825.
27. Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzman A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, **Olszewski AJ**. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. *J Hematol Oncol*. 2023;16(1):49. Epub 20230508. doi: 10.1186/s13045-023-01448-y. PubMed PMID: 37158890.
28. **Olszewski AJ**. Meet the Burkitts: a dark zone family. *Blood*. 2023;141(8):816-8. doi: 10.1182/blood.2022018509. PubMed PMID: 36821186.
29. Ollila TA, Kishkovich TP, **Olszewski AJ**, Patel NR, Jackson C, Roussel B, Niroula R, Treaba DO. Testicular Relapse of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System - a Rare Occurrence. *R I Med J* (2013). 2023;106(2):8-12. Epub 20230301. PubMed PMID: 36848533.
30. Pelcovits A, Barth P, Reagan JL, **Olszewski AJ**, Rosati V, Wood R, Sturtevant A, Winer ES. Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. *Oncologist*. 2023. Epub 20230321. doi: 10.1093/oncolo/oyad017. PubMed PMID: 36942937.
31. Di M, Keeney T, Belanger E, Huntington SF, **Olszewski AJ**, Panagiotou OA. Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study. *J Am Geriatr Soc*. 2023. Epub 20230307. doi: 10.1111/jgs.18302. PubMed PMID: 36882865.
32. De Souza AL, Mega AE, Douglass J, **Olszewski AJ**, Gamsiz Uzun ED, Uzun A, Chou C, Duan F, Wang J, Ali A, Golijanin DJ, Holder SL, Lagos GG, Safran H, El-Deiry WS, Carneiro BA. Clinical features of patients with MTAP-deleted bladder cancer. *Am J Cancer Res*. 2023;13(1):326-39. Epub 20230115. PubMed PMID: 36777505; PMCID: PMC9906077.
33. **Olszewski A**, Kurt H, Evens AM. Defining and treating high-grade B-cell lymphoma, NOS. *Blood*. 2022;140(9):943-54. Epub 2021/09/16. doi: 10.1182/blood.202008374. PubMed PMID: 34525177.
34. Ollila T, Butera J, Egan P, Reagan J, Thomas A, Yakirevich I, MacKinnon K, Margolis J, McMahon J, Rosati V, **Olszewski AJ**. Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study. *The Oncologist*. 2022;27(7):e32-e42. Epub 2022/06/01. doi: 10.1093/oncolo/oyab079. PubMed PMID: 35641232; PMCID: PMC9255974.
35. **Olszewski AJ**. Ferritin, sex, and the wildfire of inflammation in Hodgkin lymphoma. *Leuk Lymphoma*. 2022;63(4):765-7. Epub 20220202. doi: 10.1080/10428194.2022.2034161. PubMed PMID: 35105249.
36. Ollila TA, Masel RH, Reagan JL, Lu S, Rogers RD, Paiva KJ, Taher R, Burguera-Couce E, Zayac AS, Yakirevich I, Niroula R, Barth P, **Olszewski AJ**. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. *Cancer*. 2022;128(18):3319-29. Epub 20220711. doi: 10.1002/cncr.34354. PubMed PMID: 35811461; PMCID: PMC9349722.
37. Di M, Keeney T, Belanger E, Panagiotou OA, **Olszewski AJ**. Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study. *JCO Oncol Pract*. 2022;18(3):e383-e402. Epub 2021/12/01. doi: 10.1200/OP.21.00513. PubMed PMID: 34846916; PMCID: PMC8932488
38. Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, **Olszewski AJ**, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. *Blood Adv*. 2022;6(7):2035-44. Epub 2022/02/24. doi: 10.1182/bloodadvances.2021006844. PubMed PMID: 35196377; PMCID: PMC9006265.
39. Treaba DO, Bonal DM, Chorzalska A, Castillo-Martin M, Oakes A, Pardo M, Petersen M, Schorl C, Hopkins K, Melcher D, Zhao TC, Liang O, So EY, Reagan J, **Olszewski AJ**, Butera J, Anthony DC, Rintels P, Quesenberry P, Dubielecka PM. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles. *Br J Haematol*. 2023;200(6):740-54. Epub 20221110. doi: 10.1111/bjh.18513. PubMed PMID: 36354085.
40. Hsu A, Huntington KE, De Souza A, Zhou L, **Olszewski AJ**, Makwana NP, Treaba DO, Cavalcante L, Giles FJ, Safran H, El-Deiry WS, Carneiro BA. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3beta) inhibitor, in refractory adult T-Cell leukemia/lymphoma. *Cancer Biol Ther*. 2022;23(1):417-23. doi: 10.1080/15384047.2022.2088984. PubMed PMID: 35815408; PMCID: PMC9272832.

41. Epperla N, Zhao Q, Mullick Chowdhury S, Shea L, Moyo T, Reddy N, Sheets JW, Weiner DM, Ramakrishnan Geethakumari P, Kandarpa M, Jordan Bruno X, Thomas C, Churnetski MC, Hsu A, Zurbriggen LD, Tan XC, Lindsey KG, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, **Olszewski AJ**, Cohen JB, Palmisiano N, Umyarova ER, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. *Blood Adv.* 2023;7(1):88-91. doi: 10.1182/bloodadvances.2022008634. PubMed PMID: 36269847; PMCID: PMC9827027.
42. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, **Olszewski AJ**, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. *J Hematol Oncol.* 2022;15(1):96. Epub 20220716. doi: 10.1186/s13045-022-01316-1. PubMed PMID: 35842643; PMCID: PMC9287914.
43. Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordini M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, **Olszewski AJ**, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, Thompson MA. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis. *Blood Cancer Discov.* 2022. Epub 2022/03/10. doi: 10.1158/2643-3230.BCD-22-0013. PubMed PMID: 35262738.
44. Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths EA, Gulati S, Gupta S, Hwang C, Jain J, Jani C, Kaltsas A, Kasi A, Khan H, Knox N, Koshkin VS, Kwon DH, Labaki C, Lyman GH, McKay RR, McNair C, Nagaraj G, Nakasone ES, Nguyen R, Nonato TK, **Olszewski AJ**, Panagiotou OA, Puc M, Razavi P, Robilotti EV, Santos-Dutra M, Schmidt AL, Shah DP, Shah SA, Vieira K, Weissmann LB, Wise-Draper TM, Wu U, Wu JT, Choueiri TK, Mishra S, Warner JL, French B, Farmakiotis D. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. *Open Forum Infect Dis.* 2022;9(3):ofac037. Epub 20220214. doi: 10.1093/ofid/ofac037. PubMed PMID: 35198648; PMCID: PMC8860152.
45. **Olszewski AJ**, Chorzalska AD, Petersen M, Ollila TA, Zayac AS, Kurt H, Treaba DO, Reagan JL, Hsu A, Egan P, Butera J, Niroula R, Vatkevich J, Robison J, Sahin I, Jacob AP, Mullins CD, Dubielecka PM. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. *Blood Adv.* 2021. Epub 2021/09/23. doi: 10.1182/bloodadvances.2021004512. PubMed PMID: 34551072.
46. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, **Olszewski A**, Ayers EC, Landsburg DJ, Echalié B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. *Blood.* 2022;139(3):413-23. Epub 2021/09/28. doi: 10.1182/blood.2021012888. PubMed PMID: 34570876; PMCID: PMC8777199.
47. Liu MA, Keeney T, Papaila A, Ogarek J, Khurshid H, Wulff-Burchfield E, **Olszewski A**, Bélanger E, Panagiotou OA. Functional Status and Survival in Older Nursing Home Residents With Advanced Non-Small-Cell Lung Cancer: A SEER-Medicare Analysis. *JCO Oncol Pract.* 2022;18(6):e886-e95. Epub 20220207. doi: 10.1200/op.21.00460. PubMed PMID: 35130040; PMCID: PMC9191367.
48. Breakstone R, Almhanna K, Raufi A, Beard RE, Leonard KL, Renaud J, Kastura M, Dionson S, Wood R, Sturtevant A, Dipetrillo T, **Olszewski A**, Safran H. The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318. *Am J Clin Oncol.* 2022;45(8):327-32. Epub 20220623. doi: 10.1097/COC.0000000000000928. PubMed PMID: 35749747; PMCID: PMC9311474.
49. Pelcovits A, **Olszewski AJ**, Decker D, Guyer D, Leblanc TW, Egan P. Impact of Early Palliative Care on End-of-Life Outcomes in Hematologic Malignancies. *J Palliat Med.* 2021. Epub 2021/11/30. doi: 10.1089/jpm.2021.0193. PubMed PMID: 34842462.
50. Hsu A, Kurt H, Zayac AS, **Olszewski AJ**. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab. *Leuk Lymphoma.* 2021;1-12. Epub 2021/09/02. doi: 10.1080/10428194.2021.1973670. PubMed PMID: 34467833.
51. Giri S, Dahal S, Bal S, Godby KN, Richman J, **Olszewski AJ**, Williams GR, Brown C, Buford TW, Costa LJ, Bhatia S. Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma. *J Geriatr Oncol.* 2021. Epub 2021/12/21. doi: 10.1016/j.jgo.2021.12.004. PubMed PMID: 34924305.

52. Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, **Olszewski AJ**. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. *JAMA Oncol.* 2021;7(11):1714-6. Epub 2021/08/12. doi: 10.1001/jamaoncol.2021.4381. PubMed PMID: 34379085; PMCID: PMC8358793.
53. Alderuccio JP*, **Olszewski AJ***, Evens AM*, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. *Blood Adv.* 2021;5(14):2852-62. Epub 2021/07/21. doi: 10.1182/bloodadvances.2021004458. PubMed PMID: 34283175.
54. **Olszewski AJ**, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Burkitt Lymphoma International Prognostic Index. *J Clin Oncol.* 2021;39(10):1129-38. Epub 2021/01/28. doi: 10.1200/JCO.20.03288. PubMed PMID: 33502927.
55. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, **Olszewski AJ**. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study. *Haematologica.* 2021;106(7):1932-42. Epub 2021/07/01. doi: 10.3324/haematol.2020.270876. PubMed PMID: 33538152; PMCID: PMC8252937.
56. Vaughn JL, Pinheiro LC, **Olszewski A**, Epperla N. Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). *Am J Hematol.* 2021. Epub 2021/01/22. doi: 10.1002/ajh.26103. PubMed PMID: 33476433.
57. Ollila TA, **Olszewski AJ**. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. *Cancer Manag Res.* 2021;13:3935-52. Epub 2021/05/22. doi: 10.2147/CMAR.S267258. PubMed PMID: 34017197; PMCID: PMC8131013.
58. Lopresti ML, Bian JJ, Sakr BJ, Strenger RS, Legare RD, Fenton M, Witherby SM, Dizon DS, Pandya SV, Stuckey AR, Edmondson DA, Gass JS, Emmick CM, Graves TA, Cutitar M, **Olszewski AJ**, Sikov WM. Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study. *Breast Cancer Res Treat.* 2021. Epub 2021/06/05. doi: 10.1007/s10549-021-06266-9. PubMed PMID: 34086171.
59. Tohidi-Esfahani I, Warden A, Malunis E, DeNardis PL, Haurat J, Black M, Opat S, Kee D, D'Sa S, Kersten MJ, Spearing RL, Palomba ML, **Olszewski AJ**, Harrington C, Scott CL, Trotman J. WhiMSICAL: A global Waldenstrom's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. *Am J Hematol.* 2021;96(6):E218-E22. Epub 2021/03/24. doi: 10.1002/ajh.26173. PubMed PMID: 33755232.
60. Hsu A, Ohnigian S, Chang A, Liu Y, Zayac AS, **Olszewski AJ**, Reagan JL. Thrombosis in COVID-19: A Narrative Review of Current Literature and Inpatient Management. *R I Med J (2013).* 2021;104(5):14-9. Epub 2021/05/28. PubMed PMID: 34044431.
61. Di M, Huntington SF, **Olszewski AJ**. Challenges and Opportunities in the Management of Diffuse Large B Cell Lymphoma in Older Patients. *Oncologist.* 2020. Epub 2020/11/25. doi: 10.1002/onco.13610. PubMed PMID: 33230948.
62. Panagiotou OA, Keeney T, Ogarek JA, Wulff-Burchfield E, **Olszewski AJ**, Belanger E. Prevalence of functional limitations and their associations with systemic cancer therapy among older adults in nursing homes with advanced non-small cell lung cancer. *J Geriatr Oncol.* 2021;12(5):765-70. Epub 2021/02/22. doi: 10.1016/j.jgo.2021.02.007. PubMed PMID: 33610505; PMCID: PMC8184570.
63. Egan PC, LeBlanc TW, **Olszewski AJ**. End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies. *Blood Adv.* 2020;4(15):3606-14. Epub 2020/08/09. doi: 10.1182/bloodadvances.2020001767. PubMed PMID: 32766855; PMCID: PMC7422128.
64. Evens AM, Danilov AV, Jagadeesh D, Sperling AL, Kim SH, Vaca RA, (et al., >20 authors), ***Olszewski AJ**, ***Alderuccio JP** (*=equal contribution). Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. *Blood.* 2021;137(3):374-86. Epub 2020/07/15. doi: 10.1182/blood.2020006926. PubMed PMID: 32663292.

65. Ollila TA, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel NR, Dubielecka PM, Treaba DO, **Olszewski AJ**. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. *Blood*. 2021;137(8):1120-4. Epub 2020/09/03. doi: 10.1182/blood.2020007236. PubMed PMID: 32877514..
66. Rao VB, Belanger E, Egan PC, LeBlanc TW, **Olszewski AJ**. Early Palliative Care Services and End-of-Life Care in Medicare Beneficiaries with Hematologic Malignancies: A Population-Based Retrospective Cohort Study. *J Palliat Med*. 2020. Epub 2020/07/02. doi: 10.1089/jpm.2020.0006. PubMed PMID: 32609039.
67. Panagiotou OA, Keeney T, Ogarek JA, Wulff-Burchfield E, **Olszewski AJ**, Belanger E. Prevalence of functional limitations and their associations with systemic cancer therapy among older adults in nursing homes with advanced non-small cell lung cancer. *J Geriatr Oncol*. 2021. Epub 2021/02/22. doi: 10.1016/j.jgo.2021.02.007. PubMed PMID: 33610505.
68. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, (et al., >20 authors), **Olszewski AJ**, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. *Cancer Discov*. 2020. Epub 2020/07/24. doi: 10.1158/2159-8290.CD-20-0941. PubMed PMID: 32699031.
69. Zayac AS, **Olszewski AJ**. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. *Leuk Lymphoma*. 2020;61(8):1784-96. Epub 2020/04/08. doi: 10.1080/10428194.2020.1747068. PubMed PMID: 32255708.
70. Haghighyeghi K, Robinson-Bostom L, **Olszewski A**, Jackson CL, Patel NR, Sewastianik T, Carrasco RD, Shanmugam V, Treaba DO. Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides? *Am J Dermatopathol*. 2020. Epub 2020/07/18. doi: 10.1097/DAD.0000000000001725. PubMed PMID: 32675473.
71. Di M, Panagiotou OA, Reagan JL, Niroula R, **Olszewski AJ**. Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study. *Leuk Lymphoma*. 2020;61(14):3360-8. Epub 2020/09/12. doi: 10.1080/10428194.2020.1817433. PubMed PMID: 32915087.
72. Tsikala-Vafea M, Cao W, **Olszewski AJ**, Donahue JE, Farmakiotis D. Fatal Mucormycosis and Aspergillosis in an Atypical Host: What Do We Know about Mixed Invasive Mold Infections? *Case Rep Infect Dis*. 2020;2020:8812528. Epub 2020/09/11. doi: 10.1155/2020/8812528. PubMed PMID: 32908735; PMCID: PMC7471810
73. Giri S, Barth P, Costa LJ, **Olszewski AJ**. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. *J Geriatr Oncol*. 2020. Epub 2020/07/21. doi: 10.1016/j.jgo.2020.07.007. PubMed PMID: 32684352.
74. Goldman-Mazur S, Jurczynszyn A, Castillo JJ, Waszczuk-Gajda A, Grzasko N, Radocha J, (et al, >20 authors), **Olszewski AJ**, Barth P, Mikala G, Chim CS, Vesole DH. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. *Leuk Lymphoma*. 2020;61(8):1885-93. Epub 2020/04/21. doi: 10.1080/10428194.2020.1749605. PubMed PMID: 32306794.
75. Kuderer NM et al., COVID-19 and Cancer Consortium (*consortium authorship*). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020 May 28;S0140-6736(20)31187-9. doi: 10.1016/S0140-6736(20)31187-9. PMID: 32473681
76. Raufi AG, Breakstone R, Leonard K, Charpentier K, Beard R, Renaud J, Cavanaugh L, Sturtevant A, MacKinnon K, Almhanna K, **Olszewski A**, Safran HP. Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295). *Am J Clin Oncol*. 2020. Epub 2020/09/26. doi: 10.1097/COC.0000000000000762. PubMed PMID: 32976178.
77. Marks EI, Matera R, **Olszewski AJ**, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. *Am J Clin Oncol*. 2021;44(2):68-73. Epub 2020/12/11. doi: 10.1097/COC.0000000000000785. PubMed PMID: 33298767.
78. Hsu A, Liu Y, Zayac AS, **Olszewski AJ**, Reagan JL. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. *Thromb Res*. 2020;196:375-8. Epub 2020/09/28. doi: 10.1016/j.thromres.2020.09.030. PubMed PMID: 32980620; PMCID: PMC7511207.
79. Di M, Ollila TA, **Olszewski AJ**. Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. *Leukemia*. 2020 Mar 17. doi: 10.1038/s41375-020-0798-9. [Epub ahead of print] PMID: 32203140
80. Zayac AS, Hilliard RW, **Olszewski AJ**, Pelcovits A, Reagan JL, Hsu A, Riley D, Austin M, Ollila TA. Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record. *R I Med J* (2013). 2020;103(8):78-83. Epub 2020/10/03. PubMed PMID: 33003686.
81. Barth P, Giri S, Reagan JL, **Olszewski AJ**. Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma. *Am J Hematol*. 2021;96(1):14-22. Epub 2020/09/13. doi: 10.1002/ajh.25996. PubMed PMID: 32918301.

82. Goldman-Mazur S, Jurczynszyn A, Castillo JJ, Waszczuk-Gajda A, Grząsko N, Radocha J, (et al., >20 authors), **Olszewski AJ**, Barth P, Mikala G, Chim CS, Długosz-Danecka M, Grosicki S, Vesole DH. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. *Am J Hematol*. 2020 May;95(5):503-509. doi: 10.1002/ajh.25758. PMID: 32072687
83. Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, **Olszewski AJ**, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. *Blood Adv*. 2020 Jan 28;4(2):253-262. doi: 10.1182/bloodadvances.2019000875. PMID: 31945157
84. **Olszewski AJ**, Butera JN, Reagan JL, Castillo JJ. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. *Am J Hematol*. 2019 Dec 17;. doi: 10.1002/ajh.25707. [Epub ahead of print] PubMed PMID: 31849108.
85. Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Wood WA, **Olszewski A**, Basch E, Keating NL. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients with Blood Cancers. *J Natl Cancer Inst*. 2019 Dec 27;. doi: 10.1093/jnci/djz243. [Epub ahead of print] PubMed PMID: 31883008.
86. Rafelson W, **Olszewski A**. What a headache! Double-hit lymphoma with CNS recurrence - Role of chimeric antigen receptor (CAR) T-cell therapy. *Leuk Lymphoma*. 2020;61(4):757-62. Epub 2019/11/26. doi: 10.1080/10428194.2019.1695052. PubMed PMID: 31762352.
87. **Olszewski AJ**, Barth PM, Reagan JL. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. *Cancer Med*. 2019 Nov;8(16):6945-6954. doi: 10.1002/cam4.2591. PubMed PMID: 31566898.
88. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, **Olszewski AJ**, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. *Cancer*. 2020 Jan 15;126(2):293-303. doi: 10.1002/cncr.32526. PubMed PMID: 31568564.
89. Decker DP, Egan PC, Zayac AS, Treaba DO, **Olszewski AJ**. Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma. *Leuk Lymphoma*. 2020 Jan;61(1):198-201. doi: 10.1080/10428194.2019.1654097. PubMed PMID: 31432717.
90. Ollila TA, Reagan JL, **Olszewski AJ**. Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. *Leuk Lymphoma*. 2019 Dec;60(14):3426-3433. doi: 10.1080/10428194.2019.1639166. PubMed PMID: 31287335.
91. Orcutt X, Barth P, **Olszewski AJ**. Prognostic significance of upfront radiation therapy in patients with multiple myeloma. *Am J Hematol*. 2019 Jul;94(7):E190-E194. doi.org/10.1002/ajh.25492. PMID: 31006894
92. **Olszewski AJ**, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera JN, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka PM. Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. *Br J Haematol*. 2019 Aug;186(3):e31-e35. doi: 10.1111/bjh.15861. PMID: 30859554.
93. Fallah J, **Olszewski AJ**. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. *Hematology*. 2019;24(1):378-86. PMID: 30885066
94. Ollila TA, Sahin I, **Olszewski AJ**. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. *Onco Targets Ther*. 2019;12:1085-94. doi: 10.2147/OTT.S165615. PMID: 30799938
95. Barth P, Castillo JJ, **Olszewski AJ**. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. *Cancer*. 2019;125(4):550-8. doi: 10.1002/cncr.31853. PMID: 30452087.
96. **Olszewski AJ**, Castillo JJ. Ibrutinib and Rituximab in Waldenstrom's Macroglobulinemia. *N Engl J Med*. 2018;379(20):1973-4. doi: 10.1056/NEJMc1809505. PubMed PMID: 30439672.
97. Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. *Blood*. 2018;132(19):2053-66. doi: 10.1182/blood-2018-05-848408. PubMed PMID: 30213875.
98. **Olszewski AJ**, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. *J Clin Oncol*. 2018;36(28):2879-86. doi: 10.1200/JCO.2018.77.8894. PMID: 30113885
99. LeBlanc TW, Egan PC, **Olszewski AJ**. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. *Blood*. 2018 Aug 16;132(7):717-726. doi: 10.1182/blood-2018-03-842575.
100. Ollila TA, **Olszewski AJ**. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. *Curr Treat Options Oncol*. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8.

101. Ollila TA, **Olszewski AJ**. Radiation therapy in primary testicular lymphoma: does practice match the standard of care? *Leuk Lymphoma*. 2019;60(2):523-6. doi: [10.1080/10428194.2018.1480776](https://doi.org/10.1080/10428194.2018.1480776).
102. **Olszewski AJ**, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. *Br J Haematol*. 2018 May;181(4):495-504. doi: [10.1111/bjh.15224](https://doi.org/10.1111/bjh.15224).
103. **Olszewski AJ**, Zullo AR, Nering CR, Huynh JP. Use of Charity Financial Assistance for Novel Oral Anticancer Agents. *J Oncol Pract*. 2018 Apr;14(4):e221-e228. doi: [10.1200/jop.2017.027896](https://doi.org/10.1200/jop.2017.027896).
104. Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, **Olszewski AJ**, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. *Mol Oncol*. 2018 May;12(5):630-647. doi: [10.1002/1878-0261.12186](https://doi.org/10.1002/1878-0261.12186).
105. **Olszewski AJ**, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. *Am J Hematol*. 2018 Jan;93(1):E1-E3. doi: [10.1002/ajh.24921](https://doi.org/10.1002/ajh.24921).
106. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, **Olszewski AJ**, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. *Br J Haematol*. 2019;184(4):679-82. doi: [10.1111/bjh.15156](https://doi.org/10.1111/bjh.15156). PubMed PMID: 29527667.
107. Ollila TA, **Olszewski AJ**, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. *Clin Lymphoma Myeloma Leuk*. 2018 Mar;18(3):204-209. doi: [10.1016/j.clml.2018.01.007](https://doi.org/10.1016/j.clml.2018.01.007).
108. Qunaj L, Castillo JJ, **Olszewski AJ**. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. *Leuk Lymphoma*. 2018;59(6):1375-83. doi: [10.1080/10428194.2017.1387912](https://doi.org/10.1080/10428194.2017.1387912).
109. **Olszewski AJ**, Chen C, Gutman R, Treon SP, Castillo JJ. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. *Br J Haematol*. 2017 Oct;179(1):106-115. doi: [10.1111/bjh.14828](https://doi.org/10.1111/bjh.14828).
110. **Olszewski AJ**, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. *J Clin Oncol*. 2017 Oct 10;35(29):3306-3314. doi: [10.1200/JCO.2017.72.2447](https://doi.org/10.1200/JCO.2017.72.2447).
111. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, **Olszewski AJ**, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. *J Clin Oncol*. 2017 Jul 10;35(20):2260-2267. doi: [10.1200/JCO.2017.72.2157](https://doi.org/10.1200/JCO.2017.72.2157).
112. Fallah J, **Olszewski AJ**. Variation in the use of up-front chemotherapy for indolent B-cell lymphomas and chronic lymphocytic leukemia. *Hematol Oncol*. 2017 Dec;35(4):921-924. doi: [10.1002/hon.2382](https://doi.org/10.1002/hon.2382).
113. Fallah J, Qunaj L, **Olszewski AJ**. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. *Blood Advances*. 2016; 1(2):112-121. doi: <https://doi.org/10.1182/bloodadvances.2016000927>.
114. Schumacher A, Sikov WM, Quesenberry MI, Safran H, Khurshid H, Mitchell KM, **Olszewski AJ**. Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study. *PLoS One*. 2017;12(2):e0172957. doi: [10.1371/journal.pone.0172957](https://doi.org/10.1371/journal.pone.0172957).
115. Chorzalska A, Flores Kim J, Roder K, Tepper A, Ahsan N, Rao RS, **Olszewski AJ**, Yu X, Terentyev D, Morgan J, Treaba DO, Zhao T, Liang O, Gruppuso P, Dubielecka P. Long-term exposure to imatinib mesylate downregulates Hippo pathway and activates YAP in a model of chronic myelogenous leukemia. *Stem Cells Dev*. 2017 May 1;26(9):656-677. doi: [10.1089/scd.2016.0262](https://doi.org/10.1089/scd.2016.0262).
116. **Olszewski AJ**. Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma. *Leuk Lymphoma*. 2017 May;58(5):1013-1015. doi: [10.1080/10428194.2016.1262035](https://doi.org/10.1080/10428194.2016.1262035).
117. **Olszewski AJ**, Treon SP, Castillo JJ. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A population-based Analysis. *Oncologist*. 2016; 21(11):1377-1386. doi: [theoncologist.2016.0126](https://doi.org/10.1093/oncol.2016.0126).
118. **Olszewski AJ**, Gutman R, Eaton CB. Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis. *Haematologica*. 2016 Dec;101(12):e488-e491. doi: [10.3324/haematol.2016.148858](https://doi.org/10.3324/haematol.2016.148858).
119. Mantripragada KC, Hamid F, Shafqat H, **Olszewski AJ**. Adjuvant therapy for resected gallbladder cancer: analysis of the National Cancer Data Base. *J Natl Cancer Inst*. 2017 Feb;109(2). doi: [10.1093/jnci/djw202](https://doi.org/10.1093/jnci/djw202).
120. **Olszewski AJ**, Mantripragada KC, Castillo JJ. Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma. *J Natl Compr Canc Netw*. 2016 Sep;14(9):1121-9.

121. **Olszewski AJ**. Formulating a novel prognostic index for diffuse large B-cell lymphoma: T-cells break the SILENce. *Leuk Lymphoma*. 2016 Dec;57(12):2733-2735. doi: [10.1080/10428194.2016.1220009](https://doi.org/10.1080/10428194.2016.1220009)
122. **Olszewski AJ**, Fallah J, Castillo JJ. HIV-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. *Cancer*. 2016 Sep 1;122(17):2689-97. doi: [10.1002/cncr.30112](https://doi.org/10.1002/cncr.30112)
123. Mantripragada KC, **Olszewski AJ**, ..., Safran H. Clinical Trial Accrual Targeting Genomic Alterations Following Next Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. *J Oncol Pract*. 2016 Apr;12(4):e396-404. doi: [10.1200/JOP.2015.008433](https://doi.org/10.1200/JOP.2015.008433).
124. **Olszewski AJ**, Fallah J, Castillo JJ. Survival claims from observational data on cancer therapy. *J Clin Oncol*. 2016 Apr 20;34(12):1425-7. doi: [10.1200/jco.2015.64.7644](https://doi.org/10.1200/jco.2015.64.7644).
125. **Olszewski AJ**, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy: analysis of the National Cancer Data Base. *AIDS*. 2016 Mar 13;30(5):787-96. doi: [10.1097/QAD.0000000000000986](https://doi.org/10.1097/QAD.0000000000000986)
126. **Olszewski AJ**. Limits of registry data to understand survival disparities in lymphoma. *Lancet Haematol*. 2015 Nov;2(11):e459-60. doi: [10.1016/S2352-3026\(15\)00188-X](https://doi.org/10.1016/S2352-3026(15)00188-X).
127. **Olszewski AJ**, Foran JM. Health Insurance-Related Disparities in Lymphoma Survival Are Partly Mediated by Baseline Clinical Factors. *Oncologist*. 2015 Oct;20(10):1223-4. doi: [10.1634/theoncologist.2015-0228](https://doi.org/10.1634/theoncologist.2015-0228).
128. Migdady Y, Salhab M, Dang NH, Markham MJ, **Olszewski AJ**. Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. *Leuk Lymphoma*. 2016;57(3):676-84. doi: [10.3109/10428194.2015.1102246](https://doi.org/10.3109/10428194.2015.1102246).
129. **Olszewski AJ**, Shrestha R, Cook NM. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: analysis of the National Cancer Data Base. *Cancer*. 2015 Oct 1;121(19):3472-80. doi: [10.1002/cncr.29527](https://doi.org/10.1002/cncr.29527).
130. Khan H, Khan N, Ahmad A, **Olszewski AJ**, Somasundar P. Surgical management of metastatic colon cancer: A population-based analysis. *J Geriatr Oncol*. 2015 Nov;6(6):446-53. doi: [10.1016/j.jgo.2015.08.002](https://doi.org/10.1016/j.jgo.2015.08.002)
131. **Olszewski AJ**, Ali S, Witherby SM. Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. *Am J Cancer Res* 2015;5(7):2229-2240. <http://www.ajcr.us/files/ajcr0007771.pdf>
132. Fallah J, Afari ME, Cordova AC, **Olszewski AJ**, Minami T. Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease. *Case Rep Oncol Med*. 2015;2015:865383. doi: [10.1155/2015/865383](https://doi.org/10.1155/2015/865383).
133. **Olszewski AJ**, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. *Cancer Causes Control*. 2015 Aug;26(8):1163-72. doi: [10.1007/s10552-015-0610-8](https://doi.org/10.1007/s10552-015-0610-8).
134. Castillo JJ, **Olszewski AJ**, Kanan S, Meid K, Hunter ZR, Treon SP. Survival outcomes of secondary cancers in patients with Waldenström Macroglobulinemia: An analysis of the SEER database. *Am J Hematol*. 2015 Aug;90(8):696-701. doi: [10.1002/ajh.24052](https://doi.org/10.1002/ajh.24052)
135. Castillo JJ, **Olszewski AJ**, Hunter ZR, Kanan S, Meid K, Treon SP. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. *Cancer*. 2015 Jul 1;121(13):2230-6. doi: [10.1002/cncr.29334](https://doi.org/10.1002/cncr.29334)
136. **Olszewski AJ**, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the national cancer data base. *J Clin Oncol*. 2015 Feb 20;33(6):625-33. doi: [10.1200/JCO.2014.58.7543](https://doi.org/10.1200/JCO.2014.58.7543).
137. Shafqat H, Ali S, Salhab M, **Olszewski AJ**. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. *Dis Colon Rectum*. 2015 Mar;58(3):294-303. doi: [10.1097/DCR.0000000000000298](https://doi.org/10.1097/DCR.0000000000000298).
138. Castillo JJ, **Olszewski AJ**, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. *Br J Haematol*. 2015 Apr;169(1):81-9. doi: [10.1111/bjh.13264](https://doi.org/10.1111/bjh.13264).
139. **Olszewski AJ**, Shafqat H, Ali S. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. *Leuk Lymphoma*. 2015 Apr;56(4):942-50. doi: [10.3109/10428194.2014.936013](https://doi.org/10.3109/10428194.2014.936013)
140. Castillo JJ, **Olszewski AJ**, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. *Blood*. 2014 Jun 19;123(25):3999-4000. doi: [10.1182/blood-2014-05-574871](https://doi.org/10.1182/blood-2014-05-574871).
141. Khan H, **Olszewski AJ**, Somasundar P. Lymph node involvement in colon cancer patients decreases with age; A population based analysis. *Eur J Surg Oncol*. 2014 Nov;40(11):1474-80. doi: [10.1016/j.ejso.2014.06.002](https://doi.org/10.1016/j.ejso.2014.06.002).
142. **Olszewski AJ**, Winer ES, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. *Leuk Res*. 2014 Aug;38(8):866-73. doi: [10.1016/j.leukres.2014.04.009](https://doi.org/10.1016/j.leukres.2014.04.009).

143. Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D, Schorl C, Morgan J, Bryke CR, Falanga V, Zhao TC, Reagan J, Winer E, **Olszewski AJ**, Al-Homsi S, Kouttab N, Dubielecka PM. Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. *Leukemia*. 2014 Nov;28(11):2165-77. doi: 10.1038/leu.2014.120.
144. **Olszewski AJ**, Desai A. Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. *Int J Radiat Oncol Biol Phys*. 2014;88(3):642-649. doi: 10.1016/j.ijrobp.2013.11.225
145. Shafqat H, **Olszewski AJ**. Chlorambucil-induced acute interstitial pneumonitis. *Case Rep Hematol*. 2014;2014:575417. doi: 10.1155/2014/575417.
146. **Olszewski AJ**, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. *Ann Hematol*. 2014;93(3):449-458. doi: 10.1007/s00277-013-1900-4
147. Castillo JJ, Winer ES, **Olszewski AJ**. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. *Am J Hematol*. 2014;89(3):310-314. doi: 10.1002/ajh.23638.
148. Bishop KD, **Olszewski AJ**. Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis. *Int J Cancer*. 2014;134(12):2961-2971. doi: 10.1002/ijc.28625.
149. Ali S, **Olszewski AJ**. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study. *Leuk Lymphoma*. 2014 Jul;55(7):1570-7. doi:10.3109/10428194.2013.847938
150. Shafqat H, Alquadan KF, **Olszewski AJ**. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome. *Osteoporos Int*. 2014;25(3):1187-1190. doi: 10.1007/s00198-013-2533-0
151. **Olszewski AJ**, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. *Ann Oncol*. 2013 May;24(5):1352-9. doi: 10.1093/annonc/mds644
152. Castillo JJ, Winer ES, **Olszewski AJ**. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. *Cancer*. 2013;119(20):3672-3679. doi: 10.1002/cncr.28264
153. **Olszewski AJ**, Migdady Y, Boolbol S, Klein P, Boachie-Adjei K, Sakr B, et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. *Breast Cancer Res Treat*. 2013 Feb;138(1):215-23. doi: 10.1007/s10549-013-2423-3
154. Migdady Y, Sakr BJ, Sikov WM, **Olszewski AJ**. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes. *Breast*. 2013;22(5):793-798. doi: 10.1016/j.breast.2013.02.014.
155. **Olszewski AJ**, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. *J Gastrointest Cancer*. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2
156. **Olszewski AJ**, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. *Cancer*. 2013;119(3):629-38. doi: 10.1002/cncr.27773.
157. **Olszewski AJ**. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. *Am J Hematol*. 2012 Nov;87(11):E119-22. doi: 10.1002/ajh.23314.
158. Desai A, Telang GH, **Olszewski AJ**. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. *Ann Hematol*. 2013 Apr;92(4):567-8. DOI: 10.1007/s00277-012-1610-3.
159. Migdady Y, **Olszewski AJ**. Evaluation of incidental neutropenia in a multi-ethnic setting. *Int J Lab Hematol*. 2013 Feb;35(1):e6-8. DOI: 10.1111/ijlh.12016.
160. Gavini A, Telang G, **Olszewski AJ**. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. *Int J Hematol*. 2012 Mar;95(3):311-4. DOI: 10.1007/s12185-012-1012-2.
161. Casey DJ, Kim AY, **Olszewski AJ**. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma. *Am J Hematol*. 2012 May;87(5):521-4. DOI: 10.1002/ajh.22239
162. Migdady Y, **Olszewski AJ**. Paroxysmal Nocturnal Hemoglobinuria Presenting with a Left Intraventricular Thrombus in a Patient with Prior Thymoma and Aplastic Anemia. *Clinical Medicine Insights: Oncology* 2011;5 343-348. doi: 10.4137/CMO.S8442
163. **Olszewski AJ**, Grossbard ML, Kozuch P. The Horizon of Antiangiogenic Therapy for Colorectal Cancer. *Oncology (Williston Park)*. 2005 Mar;19(3):297-306.
164. **Olszewski AJ**, Grossbard ML. Empowering targeted therapy: lessons from rituximab. *Science STKE*. 2004 Jul 6;2004(241):PE30.

165. **Olszewski AJ**, Shapiro JM. Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection. *J Intensive Care Med*. 2003 May-Jun;18(3):156-9.
166. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, **Olszewski AJ**, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. *Science*. 2000 Apr 14;288(5464):335-9. DOI: 10.1126/science.288.5464.335

Book chapters and other publications

- Ferri F (ed.). *Ferri's Clinical Advisor* 2017, 1st Edition. Elsevier, 2016, ISBN 9780323280488. (Contributor, chapters "Leukemia: Chronic Lymphocytic", "Leukemia: Hairy Cell").
- Ferri F (ed.). *Ferri's Clinical Advisor* 2018, 1st Edition. Elsevier, 2017, ISBN-13: 978-0323280495. (Contributor, chapters "Leukemia: Chronic Lymphocytic", "Leukemia: Hairy Cell").
- Ferri F (ed.). *Ferri's Clinical Advisor* 2019, 1st Edition. Elsevier, 2018, ISBN-13: 978-0323530422. (Contributor, chapters "Leukemia: Chronic Lymphocytic", "Leukemia: Hairy Cell").
- Ferri F (ed.). *Ferri's Clinical Advisor* 2022, 1st Edition. Elsevier, 2021, ISBN-13: 978-0323755719. (Contributor, chapters "Leukemia: Chronic Lymphocytic", "Leukemia: Hairy Cell").
- Ferri F (ed.). *Ferri's Clinical Advisor* 2023, 1st Edition. Elsevier, 2022, ISBN-13: 978-0323755733. (Contributor, chapters "Leukemia: Chronic Lymphocytic", "Leukemia: Hairy Cell", "Hodgkin lymphoma").

Abstracts and research presentations

1. Westin J, Zhang H, Kim W, Fogliatto LM, Maruyama D, Farias DLCD, Norasetthada L, Hong H, Ozcan M, Jeon Y, Pavlovsky A, Goto H, **Olszewski A**, Shah N, Hu B, Yin S, Janousek M, Wang J, Batlevi CL, Wei MC, Budde LE. Mosunetuzumab Plus Polatuzumab Vedotin Is Superior to R-GemOx in Transplant-Ineligible Patients With R/R LBCL: Primary Results of the Phase III SUNMO Trial. *Hematological oncology*. 2025;43(S3):eLBA3_70110. doi: https://doi.org/10.1002/hon.70110_LBA3. 18th International Conference on Malignant Lymphoma, 17-21 June, 2025; Lugano, Switzerland (oral presentation).
2. **Olszewski AJ**, Matasar M, Huntington SF, Ollila T, Pelcovits A, Tiger YK, Reagan JL, Chorzalska AD, Morgan J, Pardo M, McMahon J, Yakirevich I, Donnelly S, Carmody C, Dallessandro F, Milrod C, Dubielecka PM. High Complete Response Rates and Differential Toxicity of Mosunetuzumab and Lenalidomide in Previously Untreated Follicular and Marginal Zone Lymphoma. *Hematological oncology*. 2025;43(S3):e251_70094. 18th International Conference on Malignant Lymphoma, 17-21 June, 2025; Lugano, Switzerland (poster presentation).
3. Musteata V, Spurgeon S, Karnabeda O, Di M, Gabrail N, Murthy GSG, Yin W, Upalawanna A, Zhang S, Gupta V, Yoo B, Basile FG, Dugan M, Ulrickson M, **Olszewski A**. A Phase 1 Study of SGR-1505, an Oral, Potent MALT1 Inhibitor for R/R B-Cell Malignancies, Including Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). *Hematological oncology*. 2025;43(S3):e444_70094. 18th International Conference on Malignant Lymphoma, 17-21 June, 2025; Lugano, Switzerland (poster presentation).
4. **Olszewski AJ**, Aizawa K, Karimi YH, Sano D, Oh SY, Neuhoef A, Bouyoucef-Cherchalli D, Wang J, SyBing A, Rodriguez M, Lin VTG. Phase 1b/2 Study of Maplirpacept (PF-07901801), Tafasitamab, and Lenalidomide in Transplant-Ineligible Relapsed/Refractory Diffuse Large B Cell Lymphoma Participants. *Hematological oncology*. 2025;43(S3):e808_70096. doi: https://doi.org/10.1002/hon.70096_808. 18th International Conference on Malignant Lymphoma, 17-21 June, 2025; Lugano, Switzerland (epub presentation).
5. Pelcovits A, Pardo M, Treaba D, Chorzalska AD, Dubielecka PM, Ollila T, Reagan JL, Matasar M, Huntington SF, Mani SA, **Olszewski AJ**. Spatial Transcriptomics of Follicular and Marginal Zone Lymphomas Identifies Domains of CD8+ T Cell Recruitment and Exclusion. *Hematological oncology*. 2025;43(S3):e491_70096. 18th International Conference on Malignant Lymphoma, 17-21 June, 2025; Lugano, Switzerland (epub presentation).
6. Milrod CJ, Chorzalska A, Morgan J, Pardo M, Raker C, Ollila T, Pelcovits A, McMahon JB, Donnelly S, Carmody C, Dallessandro F, Matasar M, Huntington SF, Dubielecka P, **Olszewski AJ**. Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL). 2025 American Society of Clinical Oncology Annual Meeting. May 30-June 3, 2025, Chicago, IL. Abstract 37063 (poster presentation). doi: 10.1200/JCO.2025.43.16_suppl.7063
7. Farooq U, Mehta A, Dean E, Saulitz J, Maly J, Mattar B, **Olszewski A**, Bayer R-L, Chacon V, Chu G, Gordon G, Kelley H, Graef T, Khanal R. AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. American Society of Gene and Cell Therapy 28th Annual Meeting. New Orleans, LA; May 13-17, 2025. [Abstract #858](#). (poster presentation)

8. **Olszewski AJ**, Matasar M, Huntington SF, Ollila T, Pelcovits A, Tiger YK, Reagan JL, Chorzalska AD, Morgan J, Pardo MR, McMahon J, Donnelly S, Carmody C, Margolis J, Milrod C, Dubielecka PM. Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):1644-. doi: 10.1182/blood-2024-193022. (poster presentation)
9. Milrod C, Chorzalska AD, Morgan J, Pardo MR, Raker C, Ollila T, Lee S-H, Pelcovits A, Reagan JL, McMahon J, Donnelly S, Carmody C, Margolis J, Matasar M, Huntington SF, Dubielecka PM, **Olszewski AJ**. Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma. 66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024 Blood. 2024;144(Supplement 1):1614-. doi: 10.1182/blood-2024-193023. (poster presentation)
10. Chavez JC, **Olszewski AJ**, Bastos-Oreiro M, Assouline SE, Lossos IS, Diefenbach C, Ghosh N, Modi D, Sabry W, Naik S, Shah NN, Foley R, Hodson DJ, Makadia S, Pham S, Penuel E, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Budde LE. A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):989-. doi: 10.1182/blood-2024-194581.
11. Gergis U, Martin A, Vogel A, Smith J, Klein A, Reshef R, Nath R, **Olszewski AJ**, List A, Herrera AF, Jain MD. PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL). [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):7175-. doi: 10.1182/blood-2024-210499.
12. Feldman T, Marchi E, Smith SD, **Olszewski AJ**, Huen AO, Epstein-Peterson ZD, Stevens DA, Starodub AN, Feldman EJ, Rodriguez CP, Reneau JC, Brammer JE, Mattour AH, Pinter-Brown LC, Perea R, Henrick P, Dey J, Fasciano A, Karnik R, Agarwal S, Gollerkeri A, Gollob J, Shastri A, Barta SK. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degradator of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):4433-. doi: 10.1182/blood-2024-210301.
13. Budde LE, **Olszewski AJ**, Hu B, Shah N, Batlevi CL, Yin S, To I, Wei MC, Kallemeijn M, Orellana-Noia V, Musick L, Shamas N, Pal N, Shewade A, Westin JR. Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). 2024;144(Supplement 1):2373-. doi: 10.1182/blood-2024-194340.
14. Alencar AJ, Bobek O, Mehta-Shah N, Epperla N, Lu-Emerson C, Rutherford SC, **Olszewski AJ**, Ollila T, Singer S, Dockter T, Geyer SM, Rosenstein L, De La Fuente M, Hsi ED, Dinner SN, Rubenstein JL, Bartlett NL, Leonard JP. Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):4502.4-.4. doi: 10.1182/blood-2024-209238.
15. Alderuccio JP, Khwaja J, Han S, Ghione P, Nizamuddin IA, Saha A, Dong N, Wang Y, Cherng H-JJ, Tolu SS, Wagner-Johnston N, **Olszewski AJ**, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Danilov A, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhn I, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, el-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Ollila T, Monick S, Trutzer IM, Ghosh N, Can J, Ayers A, Calabrese De Feo J, Sharp J, Treitman R, Kallam A, Okcu I, Deshani V, Baidoun F, Abeyakoon C, Hann W, Barrett A, Kahl B, Chavez JC, Cwynarski K. Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):571-. doi: 10.1182/blood-2024-199781.
16. Epperla N, Grover N, Torka P, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmán AC, Reves H, Tavakkoli M, Christian B, Thomas C, Barta SK, Ramakrishnan Geethakumari P, Shouse G, Bartlett NL, **Olszewski AJ**. Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):398-. doi: 10.1182/blood-2024-202697.
17. Epperla N, Grover N, Torka P, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmán AC, Reves H, Tavakkoli M, Christian B, Thomas C, Barta SK, Ramakrishnan Geethakumari P, Shouse G, Bartlett NL, **Olszewski AJ**. Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):2344-. doi: 10.1182/blood-2024-202721.

18. Davids MS, Ryan CE, Ren Y, Hackett L, Zhang J, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, **Olszewski AJ**, Arnason JE, Ahn IE, Brown JR. Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):1865-. doi: 10.1182/blood-2024-206556.
19. Low R, Warden A, Postek M, Denardis P, Kyriakou C, **Olszewski AJ**, Kersten MJ, Vos JMI, Thomas SK, D'Sa S, Guerin N, Harrington C, Trotman J, Tohidi-Esfahani I. Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical. 66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024. Blood. 2024;144(Supplement 1):1654-. doi: 10.1182/blood-2024-202820. (poster presentation)
20. Lee S-H, Bonal DM, Treaba DO, Pardo MR, Chorzalska AD, Reagan JL, **Olszewski AJ**, Dubielecka PM. LRP1/SDC1/TGM2/LGALS3 Stromal Signature Is Linked to Favorable Induction Chemotherapy Response in AML. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):5657-. doi: 10.1182/blood-2024-207910.
21. Hamby M, Egleston B, Frosch ZA, Steiner RE, Noy A, Carvajal V, Tolu SS, Jean-Louis G, Amengual JE, Patel R, Ahmed S, Voorhees T, Baiocchi R, Ramirez-Gamero A, Castillo JJ, Hamburger E, Dittus C, Nizamuddin IA, Mehta-Shah N, Thaw Dar NN, Sandoval-Sus J, Rojek AE, Riedell PA, Solipuram V, Rubinstein PG, Ariotti A, Suneja G, Vartanov A, Milrod C, **Olszewski AJ**, Smilnak G, Ayers E, Desai S, Rhodes JM, Magarelli G, Feldman T, Pellon M, Aboulafia DM, Bae W, Galvez C, Bhatlapenumarthi V, Hamadani M, Barta SK. Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):573-. doi: 10.1182/blood-2024-198008.
22. Gill VA, Raker C, **Olszewski AJ**, Reagan JL, Pelcovits A. Early Experience with Mosunetuzumab and Managing Cytokine Release Syndrome: Results of a Single Center Retrospective. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Blood. 2024;144(Supplement 1):2273-. doi: 10.1182/blood-2024-201724.
23. Bonal DM, Chorzalska AD, Oakes A, Pardo MR, Lee S-H, Clarke MY, Petersen M, Oh H, Brown V, Treaba DO, Reagan JL, **Olszewski AJ**, Dooner M, Morgan J, Mills J, Bertone P, Dubielecka PM. [66th ASH Annual Meeting and Exposition, San Diego, CA, 12/6-12/20/2024](#). Engrafted JAK2V617F Clone Hijacks Resident Non-Mutated Hematopoietic System to Drive Myeloproliferative Neoplasm. Blood. 2024;144(Supplement 1):754-. doi: 10.1182/blood-2024-208312.
24. **Olszewski AJ**. Management of High-Grade B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 2024;24:S41-S3. doi: 10.1016/S2152-2650(24)00340-9. 2024 SOHO Annual Meeting, Houston, September 4-7, 2024 (oral presentation).
25. Assouline S, Elizabeth Budde L, Chavez JC, Diefenbach CS, Anne Dorritie K, Ghosh N, **Olszewski AJ**, Lossos IS, Mehta A, Modi D, Naik S, Douglas Smith S, Makadia S, Pham S, Wu H, Lee Batlevi C, To I, Wei MC, Kamdar M. Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL). Clinical Lymphoma, Myeloma and Leukemia. 2024;24:S212. doi: 10.1016/S2152-2650(24)00790-0. 2024 SOHO Annual Meeting, Houston, September 4-7, 2024 (poster presentation).
26. Kurt H, Chergui A, Omer M, Reagan JL, **Olszewski AJ**. MDS-663 Improved Risk Stratification of MDS Patients With IPSS-M: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia. 2024;24:S402. doi: 10.1016/S2152-2650(24)01374-0. 2024 SOHO Annual Meeting, Houston, September 4-7, 2024 (poster presentation).
27. Assouline S, Budde LE, Chavez JC, Diefenbach CS, Dorritie KA, Ghosh N, **Olszewski AJ**, Lossos IS, Mehta A, Modi D, Naik S, Smith SD, Makadia S, Pham S, Wu H, Batlevi CL, To I, Wei MC, Kamdar M. Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL). 2024 ASCO Annual Meeting, Chicago, IL, May 29, 2024. J Clin Oncol. 2024;42(16_suppl):7021-. doi: 10.1200/JCO.2024.42.16_suppl.7021. (poster presentation)
28. Vose J, Vitolo U, Lugtenburg P, Chamuleau MED, Linton KM, Thieblemont C, Sonnevli K, Jurczak W, **Olszewski AJ**, Awan FT, Okada CY, Feldman TA, Hutchings M, Favaro E, Hoehn D, Li Z, Conlon R, Sancho J-M, Chavez JC. EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL. 2024 ASCO Annual Meeting, Chicago, IL, May 29, 2024. J Clin Oncol. 2024;42(16_suppl):7015-. doi: 10.1200/JCO.2024.42.16_suppl.7015. (oral presentation)
29. DiPetrillo TA, Garcia-Moliner M, Koffer P, Hepel JT, Khan H, Khurshid H, Abbas A, Birnbaum AE, **Olszewski AJ**, Ferreira C, Hassinger F, McCormick MC, Giesing H, Rodrigues N, Rosati V, Wood R, Webber A, Maleki S, Azzoli CG. NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2024;42(16_suppl):e20081-e. doi: 10.1200/JCO.2024.42.16_suppl.e20081.
30. **Olszewski AJ**, Eradat H, Avigdor A, Horowitz NA, Babu S, Levi I, McKinney M, Lee ST, Bergua Burgues JM, Rodriguez Izquierdo A, Bastos-Oreiro M, Ganzel C, Kim TM, Jeon Y, Taszner M, Narkhede M, Kim WS, Shin H-J, Lavie D, Woszczyk D, Dunshee D, Kapp AV, Zhou M, Batlevi CL, Ead W, Sellam G, Jurczak W. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:855. doi: <https://doi.org/10.1182/blood-2023-177588>. (oral presentation)

31. **Olszewski AJ**, Ollila T, Pelcovits A, Chorzalska AD, Morgan J, McMahon J, Donnelly S, Huntington SF, Matasar M, Reagan JL, Milrod C, Dubielecka PM. Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:1651. doi: <https://doi.org/10.1182/blood-2023-181418>. (poster presentation)
32. Budde LE, **Olszewski AJ**, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw L-Y, Wu H, To I, Wei MC, Chavez JC. Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:613. doi: <https://doi.org/10.1182/blood-2023-174209>. (oral presentation)
33. Egan P, Pelcovits A, Krar C, Donnelly S, Rubin L, Niroula R, Reagan JL, Guyer D, **Olszewski AJ**, LeBlanc TW. Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407). [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:259. doi: <https://doi.org/10.1182/blood-2023-187645>. (oral presentation)
34. Hamidi H, Kimes P, Schroeder A, Uzunovic J, **Olszewski AJ**, Sit J, Purev E, Yee D, McCord R. Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL). [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:2999. doi: <https://doi.org/10.1182/blood-2023-177591>. (poster presentation)
35. **Olszewski A**, Kahn D, Yoo B, Tan JBL, Gupta VK, Schuck E, Nie Z, Krilov G, Wright DH, Weiss D, Lachowicz J, Akinsanya K, Yin W. A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:3102. doi: <https://doi.org/10.1182/blood-2023-182838>. (poster presentation)
36. Vose JM, Feldman T, Chamuleau MED, Kim WS, Lugtenburg P, Kim TM, Costa PA, Cheah CY, Glimelius IC, Hess B, Jurczak W, Musuraca G, **Olszewski AJ**, Dinh M, Kilavuz N, Wielgos-Bonvallet M, Li T, Li Z, Eskelund C, Farooq U. Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:1729. doi: <https://doi.org/10.1182/blood-2023-180333>. (poster presentation)
37. Shastri A, Feldman EJ, Starodub AN, Feldman T, Rodriguez CP, Epstein-Peterson ZD, Stevens DA, **Olszewski AJ**, Huen AO, Porcu P, Reneau JC, Barta SK, Marchi E, Mattour AH, Pinter-Brown LC, Perea R, Donohue S, Dey J, Agarwal S, Karnik R, Gollerkeri A, Gollob J, Smith SD. Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degradator of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:3081. doi: <https://doi.org/10.1182/blood-2023-181130>. (poster presentation)
38. Epperla N, Annunzio K, Shouse GP, Grover NS, Torka P, Watkins MP, Anampa-Guzmán AC, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Ramakrishnan Geethakumari P, Karmali R, Bartlett NL, **Olszewski AJ**. Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:5147. doi: <https://doi.org/10.1182/blood-2023-185182>. (poster presentation)
39. Milrod C, Kim KW, Ollila T, **Olszewski AJ**, Pelcovits A. Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:4395. doi: <https://doi.org/10.1182/blood-2023-177626>. (poster presentation)
40. Epperla N, Grover NS, Annunzio K, Watkins MP, Torka P, Karmali R, Anampa-Guzmán AC, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Ramakrishnan Geethakumari P, Bartlett NL, Shouse GP, **Olszewski AJ**. Impact of Large Cells and Ki-67% on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - Results from a Multicenter Cohort Study. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:266. doi: <https://doi.org/10.1182/blood-2023-185152>. (oral presentation)
41. Epperla N, Annunzio K, Shouse GP, Grover NS, Torka P, Watkins MP, Anampa-Guzmán AC, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Ramakrishnan Geethakumari P, Karmali R, Bartlett NL, **Olszewski AJ**. Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:5159. doi: <https://doi.org/10.1182/blood-2023-185205>. (poster presentation)
42. Annunzio K, McLaughlin E, Voorhees T, Shea LK, Sumransub N, Rose A, **Olszewski AJ**, Bailey N, Patel K, Moyo TK, Awan FT, Ahmed G, Grover NS, Adika A, Andres EL, Faisal MS, Christian B, Anna J, Bair SM, Kendersky N, Thomas C, Torka P, Svoboda J, Carter JS, Hamadani M, Saeed H, Desai SH, Evens AM, Epperla N. Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:382. doi: <https://doi.org/10.1182/blood-2023-182389>. (oral presentation)

43. Bonal DM, Chorzalska AD, Oakes A, Pardo M, Creane Z, Lee S-H, Oyelola O, Reagan JL, **Olszewski A**, Niroula R, Donnelly S, Mills J, Bertone P, Dubielecka PM. Dysfunctional Stromal Pathways Mark Early Changes within the Bone Marrow Microenvironment in JAK2 V617F-Driven Model of Myeloproliferative Neoplasm. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:3150. doi: <https://doi.org/10.1182/blood-2023-189298>. (poster presentation)
44. Oakes A, Bonal DM, Creane Z, Oh H, Chorzalska AD, Sadler B, Reagan JL, Niroula R, **Olszewski AJ**, Haller G, Donnelly S, Dubielecka PM. Loss of Complement Factor I (Cfi) a Negative Regulator of Complement Cascade Activity Exacerbates JAK2V617F-Dependent Phenotype. [65th ASH Annual Meeting and Exposition, San Diego, CA, 12/8-12/22/2023](#). Blood. 2023;142:3149. doi: <https://doi.org/10.1182/blood-2023-189483>. (poster presentation)
45. **Olszewski AJ**, Epperla N, Chihara D, Ollila T. Immunotherapy alone versus chemoimmunotherapy as first-line treatment of marginal zone lymphoma (MZL): a real-world analysis. [17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023](#)
46. Pavlovsky A, Westin J, **Olszewski AJ**, Fogliatto L, Kim WS, Shin H, Leão D, Jeon Y, Norasetthada L, Rego E, Wu H, Yin S, Batlevi CL, Pham S, Penuel E, Jing J, Wei MC, Budde LE. SUNMO: Phase III trial of mosunetuzumab plus polatuzumab vedotin versus rituximab plus gemcitabine and oxaliplatin in relapsed/refractory aggressive non-Hodgkin lymphoma. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 doi: https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_T05.
47. Smith S, **Olszewski A**, Starodub AN, Stevens DA, Feldman T, Porcu P, Epstein-Peterson Z, Huen A, Pinter-Brown L, Mattour A, Perea R, Gollerkeri A, Dey J, Klaus C, Agarwal S, Gollob J, Shastri A. Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. https://onlinelibrary.wiley.com/doi/10.1002/hon.3164_424.
48. **Olszewski A**, Kahn D, Yoo B, Nie Z, Krilov G, Tan J, Wright H, Weiss D, Yin W, Akinsanya K. SGR-1505-101: A phase 1, open-label, multicenter, dose-escalation study of SGR-1505 as monotherapy in subjects with mature B-cell malignancies.. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.. https://onlinelibrary.wiley.com/doi/10.1002/hon.3166_OT13.
49. Hadfield, M.J., DeSouza, A., Golijanin, D., Wood, R., **Olszewski, AJ**, Holder, S.L., El-Deiry, W.S., Aggarwal, R.R., Mega, A.E., Carneiro, B.A. BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). [114th Annual AACR meeting](#), April 14-19, 2023, Orlando, FL.
50. **Olszewski AJ**, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney M, Woszczyk D, Giannopoulos K, Jurczak W, Dunshee D, Yang A, Zhou M, Qayum N, Sellam G, Horowitz NA. Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):1778-80. doi: 10.1182/blood-2022-157768.
51. **Olszewski AJ**, Budde LE, Chavez J, Ghosh N, Kamdar M, Lossos IS, Diefenbach C, Sabry W, Dorritie K, Huw L-Y, Pham S, Jia T, Wu H, To I, Wei MC, Assouline S. Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):3757-9. doi: 10.1182/blood-2022-159594.
52. **Olszewski AJ**, Huntington SF, Bannerji R, Ollila TA, McMahon J, Dubielecka PM. Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL). 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):6492-3. doi: 10.1182/blood-2022-157463.
53. Ryan CE, Lampson BL, Tyekucheva S, Hackett LR, Ren Y, Shupe SJ, Fernandes SM, Crombie JL, Ng S, Kim AI, Ahn IE, Weinstock MJ, Pazienza S, Montegaard JS, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Arnason JE, Lo S, **Olszewski A**, Brown JR, Davids MS. Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):837-8. doi: 10.1182/blood-2022-168003.
54. Jacobson CA, Jayawardena T, Yu L, Hallman J, Schmittling R, Cuneo E, Belle I, Sampey G, Cabral D, Derrick A, Tueller J, Van Besien K, Solomon SR, **Olszewski AJ**, Maakaron JE, Reshef R, Stein AS, Deol A, Jain N, List AF, Shah BD. Effective Cell Dose and Functional Attributes of Azercabtagene Zaprelucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):4588-9. doi: 10.1182/blood-2022-165311.
55. Westin J, **Olszewski AJ**, Fogliatto LM, Kim W-S, Shin H-J, Wu H, Yin S, Pham S, Penuel E, Jing J, Wei MC, Budde EL. SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):3771-2. doi: 10.1182/blood-2022-157710.

56. Annunzio K, Grover NS, Li R, Jones D, Hanel W, Christian B, **Olszewski AJ**, Epperla N. Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):3644-5. doi: 10.1182/blood-2022-164892.
57. Bhansali RS, Ellin F, Cao M, Relander T, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez JC, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain J, Ruiz M, Brammer JE, Prakash R, Iyer SP, **Olszewski AJ**, Major A, Smith SM, Riedell PA, Goldin C, Haverkos BM, Hu B, Allen PB, Toama W, Janakiram M, Brooks T, Jagadeesh D, Hariharan N, Goodman AM, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Dwivedy Nasta S, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):1481-4. doi: 10.1182/blood-2022-160090.
58. Egan PC, Pelcovits A, Leblanc TW, Krar C, Donnelly S, Rubin L, **Olszewski A**, Reagan JL, Niroula R. Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407). 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):7946-7. doi: 10.1182/blood-2022-156951.
59. Epperla N, Li R, Torka P, Shea L, Karmali R, Anampa-Guzman A, Seijung Oh T, Lindsey K, Greenwell IB, Chowdhury SM, Annunzio K, Christian B, Shouse G, Herrera AF, Bartlett NL, Grover NS, **Olszewski AJ**. Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):1926-8. doi: 10.1182/blood-2022-166785.
60. Epperla N, Zayac A, Landsburg DJ, Hughes M, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos BM, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein P, Chaudhry A, **Olszewski AJ**. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):3839-41. doi: 10.1182/blood-2022-157105.
61. Epperla N, Zhao Q, Shea L, Karmali R, Torka P, Seijung Oh T, Anampa-Guzman A, Jordan Bruno X, Umyarova E, Lindsey K, Greenwell IB, Chowdhury SM, Sawalha Y, Christian B, Grover NS, Bartlett NL, **Olszewski AJ**. Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study. 64th ASH Annual Meeting and Exposition, New Orleans, LA. Blood. 2022;140(Supplement 1):420-2. doi: 10.1182/blood-2022-158771.
62. 1. Ollila TA, Taher R, Grado S, Olszewski AJ. Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Treated with Immunochemotherapy or Chemotherapy Alone: Analysis of the National Cancer Data Base 2013-2018. Blood. 2022;140(Supplement 1):3773-4. doi: 10.1182/blood-2022-156596.
63. **Olszewski AJ**, Sharaf R, Marcus C, Kurt H, Albacker LA, Vergilio J-A, Ollila TA. CDKN2A Deletions Define an Unfavorable Subgroup within the MYD88/CD79B (MCD) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) and Are Mutually Exclusive with TP53 mutations. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):2392-. doi: [10.1182/blood-2021-146335](https://doi.org/10.1182/blood-2021-146335)
64. Zayac A, Landsburg DJ, Hughes M, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Epperla N, Bond DA, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Seijung Oh T, Vose JM, Nutsch H, Rubinstein P, Chaudhry A, **Olszewski AJ**. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):455-. doi: [10.1182/blood-2021-144308](https://doi.org/10.1182/blood-2021-144308).
65. Shah BD, Jacobson C, Solomon SR, Jain N, Johnson MC, Vainorius M, Yu L, Heery CR, List AF, He F, Reshef R, Akard LP, Sauter CS, **Olszewski AJ**, Deol A, van Besien K. Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):302-. doi: 10.1182/blood-2021-150609.
66. Jain N, Kantarjian H, Solomon SR, He F, Sauter CS, Heery CR, List AF, Johnson MC, Lou Y, Vainorius M, van Besien K, **Olszewski AJ**, Stein AS, Shah BD. Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):650-. doi: 10.1182/blood-2021-153166.
67. Sadler B, Chorzalska AD, Bonal DM, Haller G, Oakes A, Petersen M, Liu Y, **Olszewski A**, Reagan JL, Egan PC, Niroula R, Treaba DO, Hobbs G, Oh ST, Di Paola J, Baxter JE, Dubielecka PM. Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I (CFI) in Primary Myelofibrosis (PMF). 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):1472-. doi: 10.1182/blood-2021-154281.
68. Farooq F, Cardonick E, Polushkina E, Ahmed S, Ramakrishnan P, **Olszewski AJ**, Yasin H, Hamad N, Lin Y, Edmonds J, Ciavolino L, Maggen C, Fruscio R, Gziri MM, Steffensen KD, Farooq U, Amant F, Sharon E, Yin T, Figg WD, Brandt J, Peer C, Vose JM, Evens AM. A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):2457-. doi: 10.1182/blood-2021-149220.

69. Di M, **Olszewski AJ**, Keeney T, Belanger E, Panagiotou OA. Functional Status and Therapy for Nursing Home Residents with Diffuse Large B-Cell Lymphoma: A Population-Based Study. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):1918-. doi: 10.1182/blood-2021-146498.
70. Ollila TA, Masel R, Reagan JL, Paiva K, Lu S, Rogers R, Zayac A, Taher R, Yakirevich I, Niroula R, Barth P, **Olszewski AJ**. Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):3511-. doi: 10.1182/blood-2021-144304.
71. Liu J, Narendranath E, Ghobadi A, Lazaryan A, Ibrahim U, Jacobson C, Naik SG, **Olszewski AJ**, Lin Y, Chowdhury SM, Jacobs MT, Nastoupil L, Osman K, Ahmed S, Evens AM. Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD). 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):3853-. doi: 10.1182/blood-2021-149786.
72. Bhansali RS, Ganesan N, Stuver RN, Horwitz SM, Wudhikarn K, Hwang SR, Bennani N, Chavez JC, Sokol L, Saeed H, Pullarkat P, Mehta-Shah N, Prakash R, Iyer SP, **Olszewski AJ**, Goldin C, Haverkos BM, Allen P, Chong EA, Gerson JN, Landsburg DJ, Nasta S, Schuster SJ, Svoboda J, Barta SK. A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):1382-. doi: 10.1182/blood-2021-148868.
73. Tohidi-Esfahani I, Warden A, Malunis E, deNardis PL, Postek M, D'Sa S, Kersten MJ, Thomas SK, Palomba ML, **Olszewski AJ**, Guerin N, Scott C, Trotman J. Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):1343-. doi: 10.1182/blood-2021-147720.
74. Carter J, **Olszewski AJ**, Feldman TA, Karmali R, Koff JL, Ayyappan S, Lunning MA, Nakohda S, Khan N, Pelcovits A, Lofters J, Seijung Oh T, O'Leary CB, Poonsombudlert K, Tong C, Kuhn E, Liu M, Anampa-Guzman A, Shalavadi M, Thomas C, Kives M, Dong NC, Hershey A, Palmisiano N, Danilov AV, Hernandez-Ilizaliturri FJ, Barta SK, Lansigan F, Savage KJ, Evens AM. A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):50-. doi: 10.1182/blood-2021-149728.
75. **Choi Y**, Caro J, Li X, Al-Obeidi A, Kurtz SL, Kim AI, Chang JE, Olszewski AJ, Zayac A, Matthews A, Barta SK, Sundaram S, Hernandez-Ilizaliturri FJ, Leslie LA, Caimi P, Carter J, David KA, Evens AM, Kim MS, Nagle SJ, Goldberg J, Diefenbach CS. A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy. 63rd ASH Annual Meeting and Exposition, Atlanta, GA. Blood. 2021;138(Supplement 1):184-. doi: 10.1182/blood-2021-146398.
76. **Olszewski AJ**, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney M, Woszczyk D, Giannopoulos K, Jurczak W, McCord R, Xie Y, Zhou M, Qayum N, O'Hear C, Sellam G, Horowitz N. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses. SOHO (Society of Hematologic Oncology) 2021 Annual Meeting – poster ABCL-366. <https://www.sciencedirect.com/science/article/pii/S2152265021018966>.
77. **Olszewski AJ**, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney M, Woszczyk D, Giannopoulos K, Jurczak W, McCord R, Xie Y, Zhou M, Qayum N, O'Hear C, Sellam G, Horowitz N. MOSUNETUZUMAB (MOSUN) MONOTHERAPY FOR ELDERLY/UNFIT PATIENTS (PTS) WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) CONTINUES TO SHOW PROMISING SAFETY AND EFFICACY WITH DURABLE COMPLETE RESPONSES. European Hematology Association EHA2021 Virtual Congress. Poster EP503. doi: [10.1097/HS9.0000000000000566](https://doi.org/10.1097/HS9.0000000000000566)
78. Pace N, Shewade A, Kent M, Mueller L, Sellam G, O'Hear C, **Olszewski AJ**. RATIONALE FOR TREATMENT SELECTION, AND COMORBIDITIES IN OLDER PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): INSIGHTS FROM REAL WORLD DATA (RWD) European Hematology Association EHA2021 Virtual Congress. Poster EP545. doi: [10.1097/HS9.0000000000000566](https://doi.org/10.1097/HS9.0000000000000566)
79. **Olszewski AJ**, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney M, Woszczyk D, Giannopoulos K, Jurczak W, McCord R, Xie Y, Sarouei K, Qayum N, O'Hear C, Sellam G, Horowitz N. MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES. 16th International Conference on Malignant Lymphoma, Virtual Edition, ICML-16. 18–22 June, 2021. Poster 39. doi: https://doi.org/10.1002/hon.152_2880.
80. **Olszewski AJ**, Avigdor A, Babu S, Levi I, Abadi U, Holmes H, McKinney M, McCord R, Xie Y, Chen C, Sarouei K, Qayum N, O'Hear C, Sellam G, Eradat H. Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 401 – oral presentation.

81. **Olszewski AJ**, Chorzalska AD, Petersen M, Ollila TA, Zayac A, Kurt H, Treaba DO, Reagan JL, Hsu A, Egan PC, Butera J, Rafelson W, Niroula R, Vatkevich J, Robison J, Sahin I, Mullins CD, Dubielecka PM. Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 530 – oral presentation.
82. **Olszewski AJ**, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Klein A, Lossos IS, Lunning MA, Martin P, Martinex-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Yazdy MS, Smeland KB, Smith SE, Smith SD, Sundaram S, Venugopal P, Zayac A, Zhang X-Y, Zhu C, Cheah CY, El-Galaly TC, Evens AM. The Burkitt Lymphoma International Prognostic Index (BL-IPI). 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 705 – oral presentation.
83. Egan PC, Belanger E, Panagiotou OA, Rao VB, Pelcovits A, LeBlanc TW, **Olszewski AJ**. Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 218 – oral presentation.. doi: 10.1182/blood-2020-143078.
84. Di M, Keeney T, Belanger E, Panagiotou OA, **Olszewski AJ**. Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 743 – oral presentation.
85. Orellana-Noia VM, Reed DR, Sen JM, Barlow C, Malecek M-K, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik JT, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, **Olszewski AJ**, Ayers EC, Landsburg DJ, Echalié B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen JB, Portell CA. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 478 – oral presentation.
86. Alderuccio JP, **Olszewski AJ**, Evens AM, Collins GP, Danilov A, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim S-H, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy MS, Rabinovich E, Post F, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos B, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi PF, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K. Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 706 – oral presentation.
87. Ollila TA, Butera J, Egan PC, Reagan JL, Thomas AG, Yakirevich I, MacKinnon K, Margolis J, Rosati V, McMahon J, Robison J, **Olszewski AJ**. Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation.
88. Phillips TJ, **Olszewski AJ**, Munoz J, Kim TM, Yoon DH, Greil R, Westin J, Jaeger U, Canales M, Chen C, Althaus B, O'Hear C, Negricea R, Xie Y, McCord R, Purev E, Vallurupalli A. Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation. doi:10.1182/blood-2020-136295.
89. Hsu A, Zayac A, Kurt H, Olszewski AJ. CD5 Expression in Marginal Zone Lymphoma (MZL) Predicts Worse Outcomes with Rituximab (R) but Not with Bendamustine/Rituximab (BR). 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation.
90. Pelcovits A, Bakow B, Waroich J, Egan PC, Niroula R, **Olszewski AJ**, Reagan JL. Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethylators for Acute Myeloid Leukemia. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation.
91. Shewade A, **Olszewski AJ**, Pace N, Surinach A, Sellam G, Mueller L, O'Hear C. Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation. doi: 10.1182/blood-2020-136271.
92. Epperla N, Zhao Q, Chowdhury SM, Moyo TK, Shea L, Reddy N, Sheets J, Weiner DM, Ramakrishnan Geethakumari P, Kandarpa M, Jordan Bruno X, Thomas C, Churnetski MC, Hsu A, Maakaron J, Caimi P, Torka P, Bello C, Tan C, David KA, Lindsey K, Greenwell IB, Janakiram M, **Olszewski AJ**, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Barta SK, Grover NS, Bartlett NL, Sawalha Y, Christian BA, Herrera AF, Shouse G. Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation. doi: 10.1182/blood-2020-135870.

93. Tohidi-Esfahani I, Warden A, Malunis E, deNardis PL, Haurat J, Black M, Opat S, D'Sa S, Kersten MJ, Spearing R, Palomba ML, **Olszewski AJ**, Harrington C, Scott C, Trotman J. Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheel): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation. doi: 10.1182/blood-2020-138945.
94. Vaughn JL, Pinheiro LC, **Olszewski AJ**, Epperla N. Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. doi: 10.1182/blood-2020-137147. 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract – poster presentation.
95. Giri S, Bal S, Godby KN, Richman J, **Olszewski AJ**, Williams GR, Costa LJ, Bhatia S. Role of Neutrophil Lymphocyte Ratio [NLR] As a Biomarker of Frailty and Predictor of Survival Among Older Adults with Multiple Myeloma (MM). 62nd ASH Annual Meeting and Exposition December 5-8, 2020, abstract 212 – poster presentation. doi: 10.1182/blood-2020-143290.
96. Jongen-Lavrencic M, Yuda J, Mous R, Olszewski A, Nijland M, Abedin S, Calvo E, Nuthalapati S, Motwani M, Modi D, Mu Y, Petrich AM, Penugonda S, Morillo D. AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma. SOHO Society of Hematologic Oncology 2020 Annual Meeting. Poster S177. doi: 10.1016/S2152-2650(20)30708-4.
97. Ollila TA, Kurt H, Waroich J, Vakevich J, Sturtevant A, Patel N, Treaba D, Dubielecka PM, **Olszewski AJ**. Genomic subtypes correlate with the risk of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL). AACR Advances in Malignant Lymphoma, August 17-19, 2020 - poster [PO-27](#).
98. **Olszewski AJ**, Chorzalska A, Petersen M, Ollila TA, Zayac A, Kurt H, Treaba DO, Reagan JL, Hsu A, Egan PC, Butera J, Rafelson W, Niroula R, Vatkevich J, Robison J, Sahin I, Mullins CD, Dubielecka PM. Clonotypic cell-free DNA (cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas. AACR Advances in Malignant Lymphoma, August 17-19, 2020 - poster [PO-38](#).
99. **Olszewski AJ**, Chorzalska A, Treaba DO, Reagan JL, Hsu A, Egan PC, Kurt H, Butera J, Rafelson W, Ollila T, Niroula R, Robison J, Mullins CD, Dubielecka PM. Clonotypic cell-free DNA(cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas. AACR Virtual Annual Meeting II, June 22-24, [abstract 733-27](#) – poster presentation.
100. Ollila T, Kurt H, Waroich J, Vakevich J, Sturtevant A, Patel N, **Olszewski A**. Molecular predictors of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL). AACR Virtual Annual Meeting II, June 22-24, [abstract 172-6](#) – poster presentation.
101. Khan H Saiganesh H, **Olszewski AJ**, Azzoli CG, Safran H. Comparison of genomic alterations in lung cancer specimens from high and low radon zones: Search for a genomic fingerprint. AACR Virtual Annual Meeting II, June 22-24, [abstract 2338-22](#) – poster presentation.
102. **Olszewski AJ**, Lossos IS, Stadnik A, Smith SD, Jagadeesh D, Kim S, Phillips TJ, Naik S, Feldman T, Reddy N, Sundaram S, Maliske S, Kenkre VP, Epperla N, Savani M, Portell C, Palmisiano N, Klein AK, Evens AM, Burkitt Lymphoma RWE Cohort Investigators. Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites. 2020 ASCO Virtual Scientific Program, abstract [8043](#). 10.1200/JCO.2020.38.15_suppl.8043 – poster presentation.
103. Pelcovits A, Decker D, Guyer D, LeBlanc TW, **Olszewski AJ**, Egan P. Impact of palliative care on end-of-life outcomes in hematologic malignancies. 2020 ASCO Virtual Scientific Program, abstract [12026](#). doi: 10.1200/JCO.2020.38.15_suppl.12026 – poster presentation.
104. Khan H, Saiganesh H, **Olszewski AJ**, Baca Y, Kastura M, Vatkevich J, Patel N, Khurshid H, Birnbaum AE, Liu SV, Mamdani H, Kim C, Vandervalde AM, Raez LE, Socinski MA, Lopes G, Pa SG, Nieva JJ, Azzoli CG, Safran H. Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones. 2020 ASCO Virtual Scientific Program, abstract [1572](#). 10.1200/JCO.2020.38.15_suppl.1572 – poster presentation.
105. Alderuccio JP, **Olszewski AJ**, et al. Characteristics and outcomes of HIV-related Burkitt lymphoma (HIV-BL) in the post-rituximab era across 30 US cancer centers. 25th European Hematology Association Congress, 2020, abstract [S239](#) – oral presentation.
106. Jongen-Lavrencic M, Yuda J, Mous R, **Olszewski AJ**, Nijland M, Abedin S, Calvo E, Nuthalapati S, Motwani M, Modi D, Mu Y, Petrich AM, Penugonda S, Morillo D. First-in-Human Study of a TRAIL Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma. 25th European Hematology Association Congress, 2020, abstract [EP589](#) – poster presentation.
107. Waroich J, **Olszewski AJ**, Kurt H, Vatkevich J, Sturtevant A, Patel N, Ollila T. Molecular predictors of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL). 2020 ASCO Virtual Scientific Program, abstract [e20082](#). 10.1200/JCO.2020.38.15_suppl.e20082 – e-publication.
108. **Olszewski AJ**, Davids MS, Yakirevich I, Egan PC. Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation.

109. Rao VB, Belanger E, Egan PC, LeBlanc TW, **Olszewski AJ**. Rao V, Olszewski AJ, Egan PC, LeBlanc TW, Belanger E. Billed palliative care services and end-of-life care in patients with hematologic malignancies. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation.
110. Zayac A, Evens AM (... , 50 authors), Lossos IS, **Olszewski AJ**. Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation.
111. Evens AM, Danilov A (... , 50 authors), **Olszewski AJ**, Alderuccio JP. The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-oral presentation.
112. **Olszewski AJ**, Ollila TA, Reagan JL. Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
113. **Olszewski AJ**, Chorzalska AD, Treaba DO, Reagan JL, Egan PC, Kurt H, Butera J, Rafelson W, Mohler AC, Ollila TA, Niroula R, Robison J, Mullins CD, Dubielecka PM. Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
114. Barth P, Giri S, Reagan JL, **Olszewski AJ**. Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
115. Giri S, Barth P, Costa LJ, **Olszewski AJ**. Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
116. Rhodes JM, Sundaram S, Zayac A, **Olszewski AJ**, Caimi P, Braunstein Z, Brammer JE, Jehangir W, Umyarova E, Sheela S, Ghosh N, Nasta SD, Barta SK. Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA). 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
117. Di M, Ollila TA, **Olszewski AJ**. Exposure to Ibrutinomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
118. Di M, **Olszewski AJ**. Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
119. Zayac A, Egan PC, Ollila TA, **Olszewski AJ**, Barth P, Quesenberry MI, Butera J, Fast LD, Niroula R, Quesenberry PJ, Reagan JL. Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
120. Mao C, **Olszewski AJ**, Egan PC, Barth P, Reagan JL. Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia. 61st ASH Annual Meeting and Exposition. Orlando, FL, December 7-10, 2019-poster presentation.
121. Rao V, **Olszewski AJ**, Egan PC, LeBlanc TW, Belanger E. Billed palliative care services and end-of-life care in patients with hematologic malignancies. 2019 Supportive Care in Oncology Symposium. San Francisco, CA, October 26, 2019-oral presentation at a non-plenary session.
122. **Olszewski AJ**, Barth P, Giri S, Reagan J. Comparative effectiveness of lenalidomide, bortezomib, and their combination as first-line treatment of older patients with myeloma. 17th International Myeloma Workshop, Boston, MA, September 12-15, 2019—oral presentation.
123. Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D'Sa S, Kersten MJ, Palomba ML, Spearing R, Thomas S, **Olszewski AJ**, Scott C, Harrington C, Trotman J. PF495 WHIMSICAL (WALDENSTRÖM'S MACROGLOBULINEMIA STUDY INVOLVING CART-WHEEL): A GLOBAL PATIENT-DERIVED DATA REGISTRY MAPPING TREATMENT AND QUALITY OF LIFE DATA. 24th Congress of the European Hematology Association (EHA) Amsterdam, June 13-16, 2019. Poster PF495. doi: [10.1097/01.HS9.0000560280.92775.52](https://doi.org/10.1097/01.HS9.0000560280.92775.52)
124. **Olszewski AJ**, Ollila T, Reagan JL. Rituximab alone (R) versus rituximab plus bendamustine (BR) for splenic (SMZL) and nodal marginal zone lymphoma (NMZL). Hematological Oncology. 2019;37(S2):225-6. doi: 10.1002/hon.40_2630. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019—poster presentation.
125. Tohidi-Esfahani I, Warden A, Malunis E, DeNardis P, Bomsztyk J, D'Sa S, Kersten M, Palomba M, Spearing R, Thomas S, **Olszewski AJ**, Scott C, Harrington C, Trotman J. WhiMSICAL (Waldenström's macroglobulinemia study involving cart-wheel): a global patient-derived data registry mapping treatment and quality of life. Hematological Oncology. 2019;37(S2):234-5. doi: 10.1002/hon.46_2630. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019—poster presentation.

126. Budde LE, Vallurupalli A, Babu S, Lossos IS, Alderuccio JP, Chavez JC, Eradat H, Holmes H, Hamadani M, Karur VG, **Olszewski AJ**, Seymour E, Althaus B, Medeiros BM, Li CC, Kwan A, Wei MC, Yin S, O'Hear C, Munoz J. Ongoing phase 1b/2 trials of mosunetuzumab investigating novel treatment regimens for patients with B-cell non-Hodgkin lymphoma (NHL). *Hematological Oncology*. 2019;37(S2):564-6. doi: 10.1002/hon.12_2632. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 June, 2019—poster presentation.
127. **Olszewski AJ**, Barth P, Reagan JL. Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 709)—oral presentation.
128. Di M, **Olszewski AJ**. Adjuvant Chemotherapy Administration and Survival Outcomes in Lymphoma Survivors with Common Solid Tumors: A Population-Based Study. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 621)—oral presentation.
129. Egan PC, LeBlanc TW, **Olszewski AJ**. End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 829)—oral presentation.
130. **Olszewski AJ**, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera J, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka P. Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 3841)—poster presentation.
131. Ollila TA, Reagan JL, **Olszewski AJ**. Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 2913)—poster presentation.
132. Decker D, Egan PC, Treaba DO, **Olszewski AJ**. Survival and Risk of Central Nervous System Recurrence in Burkitt or High-Grade B-Cell Lymphoma in the DA-EPOCH-R Era. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 2983)—poster presentation.
133. Orcutt X, Barth P, **Olszewski AJ**. Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 3230)—poster presentation.
134. Ollila TA, Zayac A, **Olszewski AJ**, Hilliard RW, Riley D, Pelcovits A, Austin MR, Keane M, Reagan JL. Enforcing the 4T: Including a Hard Stop 4T Calculator into the Electronic Medical Record for Heparin Induced Thrombocytopenia. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 2442)—poster presentation.
135. Chorzalska AD, Morgan J, Petersen M, Treaba DO, **Olszewski AJ**, Reagan JL, Dubielecka P. Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 1285)—poster presentation.
136. Kothari SK, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess BT, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, **Olszewski AJ**, Lee SS, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 451)—oral presentation.
137. Ayers EC, Li S, Medeiros J, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy N, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach C, Faramand R, Chavez JC, **Olszewski AJ**, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline S, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. 60th ASH Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018 (Abs 453)—oral presentation.
138. **Olszewski AJ**, Egan P, Decker D, Treaba D. Survival Outcomes and Risk of Central Nervous System (CNS) Recurrence in Burkitt (BL) or High-Grade B-Cell Lymphoma (HGBCL) in the DA-EPOCH-R Era. European School of Haematology (ESH) 4th Annual International Conference on New Concepts in Lymphoid Malignancies, Saggart (Dublin), Ireland, September 28-30th, 2018—poster presentation.
139. **Olszewski AJ**, Egan P, LeBlanc TW. Hospice use among Medicare fee-for-service (FFS) or managed-care organization (MCO) enrollees with leukemia and myeloma. 2018 ASCO Annual Meeting, Chicago, IL. June 4, 2018 (Abs 10025)—poster presentation.
140. Ollila T, **Olszewski AJ**. Radiation therapy in primary testicular lymphoma (PTL): Does practice match the standard of care? 2018 ASCO Annual Meeting, Chicago, IL. June 4, 2018 (Abs 7544)—poster presentation.
141. **Olszewski AJ**, Treon SP, Castillo JJ. Application and Outcomes of Bendamustine- or Bortezomib-Based Therapy for Waldenstrom's Macroglobulinemia. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 348)—oral presentation.

142. **Olszewski AJ**, Egan PC, LeBlanc TW. Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 277)—oral presentation.
143. Guerrero T, Bibas M, Baldini F, Cartron C, Cwynarski K, Dierickx D, Lansingan F, Linnik YA, Mogollon R, Navarro JT, Ninkovic S, **Olszewski AJ**, Reagan JL, Tchemonog E, Tousseyn T, Castillo JJ. Use of Bortezomib-Containing Regimens in the Frontline Treatment of Patients with Plasmablastic Lymphoma: A Multicenter Retrospective Analysis. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 1580)—poster presentation.
144. Chorzalska AD, Morgan J, Treaba DO, **Olszewski AJ**, Lombardo K, Zini R, Pacilli A, Tepper A, Reagan JL, Kotula L, Quesenberry PJ, Gruppuso P, Manfredini R, Vannucchi AM, **Dubielecka P**. Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-kb Signaling to Pathogenesis of Myeloproliferative Neoplasms. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 4210)—poster presentation.
145. Chorzalska AD, Ahsan N, Tepper A, Hines S, Treaba DO, **Olszewski AJ**, Reagan JL, Gruppuso P, **Dubielecka P**. Map3k8/COT1/Tpl2 Drives Resistance to Bcr-Abl1 Inhibition through Activation of MEK-ERK and NF-Kb Pathways. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 2529)—poster presentation.
146. Ollila T, **Olszewski AJ**, Quesenberry PJ, Quesenberry MI, Butera J, Reagan HL. Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia. 59th ASH Annual Meeting & Exposition, Atlanta, GA, December 9-12, 2017 (Abs 1428)—poster presentation.
147. Leblanc TW, **Olszewski AJ**. Use of hospice services among Medicare beneficiaries with acute and chronic leukemias. 2017 ASCO Palliative and Supportive Care in Oncology Symposium; San Diego, CA, October 27-28, 2017 ([Abs 68](#))—poster presentation.
148. **Olszewski AJ**, Castillo JJ. Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis. 14th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 14-17, 2017 (Abs 222)—poster presentation.
149. **Olszewski AJ**, Dusetzina S, Davidoff AJ, Trivedi AN. Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents. 2017 ASCO Annual Meeting, Chicago, IL. June 2-6, 2017 (Abs 6522)—poster presentation.
150. Castillo JJ, **Olszewski AJ**. Outcomes of secondary cancers among myeloma survivors. 2017 ASCO Annual Meeting, Chicago, IL. June 2-6, 2017 (Abs 8043)—poster presentation.
151. Khudayar H, Fallah J, Souaid R, **Olszewski AJ**. Mammography use, incidence, and survival of primary breast lymphoma. 2017 ASCO Annual Meeting, Chicago, IL. June 2-6, 2017 (Abs e13087).
152. **Olszewski AJ**, Eaton CB, Trivedi AN. Association of Medicare Part D Coverage and Low-Income Subsidies with Use of Novel Oral Agents in Multiple Myeloma. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 686)—oral presentation.
153. **Olszewski AJ**, Treon SP, Castillo JJ. Comparative Effectiveness of Rituximab-Based Immunochemotherapy in Waldenstrom's Macroglobulinemia. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 2986)—poster presentation.
154. Qunaj L, Castillo JJ, **Olszewski AJ**. CD20-Negative Large B-Cell Lymphomas: Analysis of the National Cancer Data Base. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 4226)—poster presentation.
155. Fallah J, **Olszewski AJ**. Variation in the Use of Splenectomy for Splenic Lymphomas: Analysis of the National Cancer Data Base. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 3584)—poster presentation.
156. Reagan JL, Ollila T, Dubielecka PM, **Olszewski AJ**. Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 1994)—poster presentation.
157. Chorzalska AD, Morgan J, Treaba DO, **Olszewski AJ**, ..., Dubielecka PM. Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFkB. 58th ASH Annual Meeting, San Diego, CA. December 3-6, 2016. (Abs 1203)—oral presentation.
158. Mantripragada KC, Hamid F, **Olszewski AJ**. Adjuvant therapy for gallbladder carcinoma (GBCA): Analysis of the National Cancer Data Base (NCDB). 2016 ASCO Annual Meeting, Chicago, IL. June 2016 (Abs. 4082)—poster presentation.
159. Qunaj L, Fallah J, **Olszewski AJ**. Therapy and outcomes of primary central nervous system lymphoma (PCSNL) in the United States: Analysis of the National Cancer Data Base (NCDB). 2016 ASCO Annual Meeting, Chicago, IL. June 2016 (Abs. 2026)—poster presentation.
160. Fallah J, **Olszewski AJ**. Variation in the administration of early chemotherapy for indolent lymphomas: Analysis of the National Cancer Data Base (NCDB). 2016 ASCO Annual Meeting, Chicago, IL. June 2016 (Abs. e18005)—electronic abstract.
161. Hamid F, Shafqat H, Matripragada K, Guerrero T, Somadundar P, Olszewski AJ. Outcomes of multimodality therapy for gallbladder cancer in the United States (US): Analysis of the National Cancer Data Base (NCDB). ASCO 2016 Gastrointestinal Cancers Symposium—poster presentation.

162. **Olszewski AJ**, Gutman R, Eaton CB. Increased Fracture Risk in Patients with Untreated Chronic Lymphocytic Leukemia (CLL): A Population-Based Analysis. 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—oral presentation (abstract #878).
163. **Olszewski AJ**, Fallah J, Eaton CB, Treon SP, Castillo JJ. The Evolution of Management and Survival Outcomes of Waldenström Macroglobulinemia (WM) in the United States (US). 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—oral presentation (abstract #882).
164. **Olszewski AJ**, Castillo JJ. Prognosis of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #3861).
165. Fallah J, Thomas AG, **Olszewski AJ**. Watchful Waiting As Initial Management of Advanced-Stage Follicular Lymphoma in the Rituximab Era: Analysis of the National Cancer Data Base. 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #2692).
166. Chorzalska A, Kim JF, Roder K, **Olszewski AJ**, Terentyev D, Dubielecka PM. Downregulation of Mir-181a Restores Chemosensitivity to Imatinib Mesylate in Chronic Myeloid Leukemia Cells Resistant to Tyrosine Kinase Inhibitors. 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #4016).
167. Matripragada K, Castillo JJ, **Olszewski AJ**. Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL). 57th ASH Annual Meeting & Exposition, December 5-8, 2015, Orlando, FL—poster presentation (abstract #3914).
168. **Olszewski AJ**, Castillo JJ. Management of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). 2015 ASH Meeting on Hematologic Malignancies, Chicago IL. September 2015—oral presentation.
169. Fallah J, Thomas AG, **Olszewski AJ**. Abbreviated Chemotherapy and Radiation for Early-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the R-CHOP Era: Analysis of the National Cancer Data Base (NCDB). 2015 ASH Meeting on Hematologic Malignancies, Chicago IL. September 2015—oral presentation.
170. **Olszewski AJ**, Mantripragada K, Castillo JJ. Risk Factors for Early Death after Rituximab-Based Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL). 2015 ASH Meeting on Hematologic Malignancies, Chicago IL. September 2015 (Abs. 48)—poster presentation.
171. **Olszewski AJ**, Fallah J, Castillo JJ. Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL) in the United States (US): Analysis of the National Cancer Data Base (NCDB). 2015 ASCO Annual Meeting, Chicago, IL. May 2015 (Abs. 1521)—poster presentation.
172. Saleh MN, Sakr BJ, Witherby SM, **Olszewski AJ**, Sikov WM. Breast cancer recurrence in older patients with clinically node-negative T1-T2 tumors managed without sentinel node biopsy (SNB) and without adjuvant radiation therapy. 2015 ASCO Annual Meeting, Chicago, IL. May 2015 (Abs. 528)—poster presentation.
173. Ahmad A, Khan H, **Olszewski AJ**, Somasundar P. Nodal Involvement in Gastric Adenocarcinoma Decreases with Age: A Population-based Analysis. SSO 68th Annual Cancer Symposium. Houston, TX, March 25-29, 2015—poster presentation ([Abs. P364](#)).
174. Castillo JJ, **Olszewski AJ**, Kanan S, Meid K, Hunter Z, Treon SP. Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia. 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014—oral presentation (abs. 855).
175. Shrestha R, Cook NM, **Olszewski AJ**. Race-Specific Features and Treatment Patterns of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) in the United States: Analysis of the National Cancer Data Base. 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014—poster presentation (abs. 2594).
176. **Olszewski AJ**. Utility of the International Prognostic Index (IPI), Revised IPI and a Model-Based Score for Risk Stratification of Diffuse Large B-Cell Lymphoma (DLBCL) in the National Cancer Data Base (NCDB). 56th ASH Annual Meeting and Exposition, San Francisco, CA. December 6-9, 2014—poster presentation (abs. 1308).
177. **Olszewski AJ**, Ali S, Witherby SM. Survival trends in histologic subtypes of metastatic non-small cell lung cancer (mNSCLC) in the United States: 2000-2010. The ASTRO, ASCO and IASLC 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. October 30 – November 1, 2014, Chicago, IL. Published in: [Int J Radiat Oncol Biol Phys 90: S57-S58](#).
178. Chorzalska A, Salloum I, Treaba D, Schorl C, Morgan J, Bryke C, Reagan J, Wine E, **Olszewski AJ**, Dubielecka P. New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance. 43rd Annual Scientific Meeting of the ISEH – International Society for Experimental Hematology. 21-24 August, 2014, Montreal, Canada (Abs.1034)—poster presentation. Published in: [Experimental Hematology. 2014 Aug;42\(8\):S31](#).
179. Shrestha R, Castillo JJ, **Olszewski AJ**. Chemotherapy or combined modality therapy for early-stage Hodgkin lymphoma: A comparative, population-based study. ASCO 2014 50th Annual Meeting, Chicago, IL. May 2014 (Abs. 125495)—poster presentation.

180. Shafqat H, Ali S, Salhab M, **Olszewski AJ**. Survival of high-grade neuroendocrine carcinomas (HGNEC) of the colon and rectum: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. ASCO 2014 50th Annual Meeting, Chicago, IL. May 2014 (Abs. 125582)—poster presentation.
181. Chorzalska A, Schorl C, Dubielecka P, Salloum I, Morgan J, Treaba D, Winer ES, Reagan JL, **Olszewski AJ**. Cellular level of Abelson interactor-1 as a marker predicting chemoresistance. ASCO 2014 50th Annual Meeting, Chicago, IL. May 2014 (Abs. 135188)—poster presentation.
182. Khan H, **Olszewski AJ**, Somasundar P. Surgical Management of Metastatic Colon Cancer in Elderly: Analysis of the Surveillance, Epidemiology and End Results (SEER) Database. Fourteenth Annual Americas Hepato-Pancreato-Biliary Congress 19-23 February 2014, Miami Beach, FL, USA—oral presentation.
183. Khan H, Somasundar P, **Olszewski AJ**. Nodal involvement and impact of adequate staging in older patients with resectable colon cancer: A population-based analysis. J Clin Oncol 32, 2014 (suppl 3; abstr 424). 2014 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 16-18 January, 2014—poster presentation.
184. **Olszewski AJ**, Ali S, Shafqat H. Survival After Rituximab-Based Chemoimmunotherapy In Older Patients With Follicular, Nodal Marginal Zone and Small Lymphocytic Lymphoma: Analysis Of SEER-Medicare Data. Blood 2013 122:1736. ASH Annual Meeting, New Orleans, LA. December 2013—poster presentation.
185. Migdady Y, Salhab M, **Olszewski AJ**. Living In Remission: Disparities In Conditional Survival Among Non-Hodgkin Lymphoma Survivors. Blood 2013 122:2915. ASH Annual Meeting, New Orleans, LA. December 2013—poster presentation.
186. Desai A, **Olszewski AJ**. Evaluation of the physician-patient communication assessment tool (CAT) in a hematology-oncology practice. J Clin Oncol 31, 2013 (suppl 31; abstr 14)—2013 ASCO Quality Care Symposium, San Diego, CA, November 2013—poster presentation.
187. **Olszewski AJ**. Comparative outcomes of splenectomy and rituximab-based chemotherapy in elderly patients with splenic marginal zone lymphoma. J Clin Oncol 31, 2013 (suppl; abstr 8549) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation.
188. Ali S, **Olszewski AJ**. Nodular lymphocyte-predominant and classical Hodgkin lymphoma subtypes: Differences in biology, survival, and impact of radiotherapy. J Clin Oncol 31, 2013 (suppl; abstr 8550) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation.
189. Bishop K, **Olszewski AJ**. Melanoma of ocular, mucosal, and genital sites: Epidemiology and survival outcomes. J Clin Oncol 31, 2013 (suppl; abstr 9051) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation.
190. Taber AM, Khurshid H, Perez K, Birnbaum AE, **Olszewski AJ**, Luppe D, Jean M, Rosati K, Safran H. Phase I study of ridaforolimus with cetuximab for patients with advanced non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer. J Clin Oncol 31, 2013 (suppl; abstr 8075) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation.
191. Austin TC, Perez K, Fontes-Borts L, Luppe D, Jean M, **Olszewski AJ**, Rosati K, Rathore B, Safran H. A phase II study of cabazitaxel in patients with previously treated metastatic gastroesophageal adenocarcinoma. J Clin Oncol 31, 2013 (suppl; abstr e15095) ASCO 49th Annual Meeting 2013, Chicago, IL —poster presentation.
192. Shao T, **Olszewski AJ**, Boolbol SK, Migdady Y, Boachie-Adjei K, Sakr BJ, Klein P, Sikov W. Disease-related outcomes with adjuvant chemotherapy in HER2 positive or triple negative T1a/bN0 breast cancers. SABCS 2012, Abstr. P6-07-34. doi: 10.1158/0008-5472.SABCS12-P6-07-34—poster presentation.
193. **Olszewski AJ**. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: Analysis of the surveillance, epidemiology and, end results (SEER)-Medicare database. ASCO 2013 Gastrointestinal Cancers Symposium, Abstr.75—poster presentation.
194. Perez K, Pricolo V, Vrees M, Dipetrillo T, Oldenberg N, Klipfel A, Schechter S, Kinsella T, Roth L, Cataldo T, Shah N, **Olszewski A**, Isdale D, Safran H, Sikov W: A Phase II Study of Complete Neoadjuvant Therapy in Rectal Cancer (CONTRE): The Brown University Oncology Group. ASCO 2013 Gastrointestinal Cancers Symposium, Abstr.335—poster presentation.
195. Desai A, Kuritzky B, Castillo JJ, **Olszewski AJ**: Vertebral Compression Fractures in Patients with Chronic Lymphocytic Leukemia: Incidence and Risk Factors. ASH Annual Meeting, Abstr 4586.
196. **Olszewski AJ**, Desai A: Radiotherapy in Stage I and II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT): Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. ASH Annual Meeting 2012, Abstr. 2053—poster presentation.
197. **Olszewski AJ**. Survival with splenectomy in splenic marginal zone lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. J Clin Oncol 30, 2012 (suppl; abstr 8044), ASCO 48th Annual Meeting 2012, Chicago, IL —poster presentation.
198. Castillo JJ, **Olszewski AJ**. Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. J Clin Oncol 30, 2012 (suppl; abstr 8045), ASCO 48th Annual Meeting 2012, Chicago, IL —poster presentation.

199. Migdady Y, Sikov WM, Sakr BJ, **Olszewski AJ**. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. J Clin Oncol 30, 2012 (suppl; abstr 1034), ASCO 48th Annual Meeting 2012, Chicago, IL—poster presentation.
200. **Olszewski AJ**, Malamud S, Grossbard ML, Mirzoyev T, Dietrich M, Thurakal A, Rodriguez T, Kozuch P. Phase I dose-finding study of biweekly oxaliplatin (E) in combination with gemcitabine (G), 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (G-FLIE) in patients with solid tumors. Proc ASCO 2005: Abs#4202.

Invited presentations

1. **“Updates on lymphoma from ASCO 2024”**. ASCO Direct™ Highlight: 2024 Official Annual Meeting Review; October 5, 2024; Providence, RI
2. **“Management of High Grade B-Cell Lymphoma”** SOHO 2024 Annual Meeting, Houston, TX. [September 4-7, 2024](#).
3. **“A critical vision on treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma”**. [Brazilian Lymphoma Conference](#), Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH). Virtual, [April 24, 2024](#).
4. **“Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated DLBCL”**. Post-ASH 2023 Lymphoma & CLL highlights webinar. VJHemOnc, [Jan 24, 2024](#)
5. **“Bringing immunotherapy to first-line treatment for B-cell lymphomas”** Legoretta Cancer Center Translational Research Disease Group seminar, Providence, RI. October 26, 2023.
6. **“Burkitt lymphoma”** European School of Oncology, 2024 Certificate of Competence in Lymphoma.
7. **“Is There Still a Role for CNS Prophylaxis in Large B-Cell Lymphoma?”** SOHO 2023 Annual Meeting, Houston, TX. [September 6, 2023](#).
8. **“How Do We Choose among non-CAR-T Options for Patients with Recurrent Aggressive Lymphoma”**. Great Debates & Updates in Hematologic Malignancies, Boston, MA. [August 17, 2023](#).
9. **“Debate - CNS Prophylaxis in Aggressive Lymphoma – Aggressive”**. Great Debates & Updates in Hematologic Malignancies, Boston, MA. [August 17, 2023](#).
10. **“Central nervous system prophylaxis in aggressive B-cell lymphomas”**. Great Debates & Updates in Hematologic Malignancies, New York City, NY. April 14 2023.
11. **“Mosunetuzumab: A chemotherapy-free option for chemotherapy-ineligible patients with DLBCL”** DAVA Oncology 10th Global Summit on Hematological Malignancies, Whistler BC; March 31, 2023
12. **“Updates on lymphoma from ASCO 2022”**. ASCO Direct™ Highlight: 2022 Official Annual Meeting Review; October 1, 2022; Providence, RI
13. **“Diffuse large B-cell lymphoma”**. Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management. Harvard Medical School, April 2, 2022.
14. **“Burkitt lymphoma”**. University of Chicago 19th Annual International Ultmann Chicago Lymphoma Symposium. Chicago, April 29 – 30, 2022.
15. **“Aggressive B-cell lymphoma”** - 2021 Virtual East Coast Lymphoma Workshop. Lymphoma Research Foundation. March 26, 2022.
16. **“Burkitt lymphoma – state of the art and future directions”**. [Lymphoma 2022](#): State of the Art and Future Directions virtual conference. February 24, 2022.
17. **“Burkitt lymphoma”** – 26th Annual North American Virtual Educational Forum on Lymphoma. Lymphoma Research Foundation. October 16, 2021.
18. **“Best of ASCO 2021: lymphoma”**. ASCO Direct™ Highlight: 2021 Official Annual Meeting Review; October 2, 2021; Providence, RI
19. **“Molecular predictors of central nervous system recurrence in aggressive lymphoma”**, 2021 Virtual North East Regional IDeA Conference v-NERIC 2021, August 17, 2021 ([virtual](#))
20. **“Burkitt lymphoma”**. Brazilian Symposium on Onco-Hematology. August 21, 2021 ([virtual](#)).

21. **"Updates in the Management of CLL"**. December 15, 2020; Roger William Medical Center, Providence, RI.
22. **"Best of ASCO 2020: non-Hodgkin lymphoma"**. ASCO Direct™ Highlight: 2020 Official Annual Meeting Review; September 12, 2020; Brown Medicine, Providence, RI
23. **"Molecular Tools for Diagnosis and Risk Prediction of Central Nervous System Involvement in Non-Hodgkin Lymphoma"** – [Advance-CTR](#) Translational Research Seminar Series, September 10, 2020; Brown University, Providence, RI
24. **"Estimating Treatment Effects from secondary data: novel therapies in hematological malignancies"** – Population Science Group Seminar, July 10, 2019; Brown University, Providence, RI.
25. **"Aggressive B-cell non-Hodgkin lymphoma"** - 2019 New England Lymphoma Workshop, Boston, MA. March 23, 2019.
26. **"Is there a standard of care for treatment-naïve Waldenström macroglobulinemia?"** – Keynote speaker. 10th International Workshop on Waldenström's Macroglobulinemia (IWWM10), October 11-14, 2018, New York City, NY, USA
27. **"Aggressive B-cell non-Hodgkin lymphoma"** - 2018 New England Lymphoma Workshop, Boston, MA. April 28, 2018.
28. **"Using big data to address disparities in access to cancer therapy"**. 3rd Annual Rhode Island Research Breakfast. American Cancer Society, October 14, 2016. (The Hope Club, Providence, RI).
29. **"Updates in Hematology/Oncology-Immunotherapy"**, Grand Rounds at the Department of Medicine, Memorial Hospital of Rhode Island. January 27, 2016. Pawtucket, RI.
30. **"The promise and perils of using population registries for assessment of treatment in oncology"** Grand Rounds at the Division of Hematology-Oncology, Rhode Island Hospital. October 15, 2015. Providence, RI.
31. **"Emergent treatments for lymphomas: new opportunities and challenges"**, Grand Rounds at the Department of Medicine, Memorial Hospital of Rhode Island. October 1, 2014. Pawtucket, RI.
32. **"Care of the cancer survivors"**, Grand Rounds at the Department of Family Medicine, Memorial Hospital of Rhode Island. May 7, 2014. Pawtucket, RI.
33. **"Using big data for assessment of treatment effects in oncology"**, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, May 5, 2014. Boston, MA.
34. **"Management of chronic lymphocytic leukemia, 2014 update"**, Roger William Medical Center, March 11, 2014. Providence, RI.
35. **"Causal inference in observational studies – a practical approach"**, Grand Rounds at The Brown University Center of Primary Care and Prevention. April 10, 2013. Pawtucket, RI.
36. **"Latinos hablemos claro sobre cancer"**. 5th Annual Latino Cancer Control Task Force Conference, October 20, 2010. Providence, RI

Other presentations

- Ollila T, Olszewski AJ. Early Unfavorable Hodgkin Lymphoma in the era of bleomycin shortage. New England Lymphoma Rounds. Lymphoma Research Foundation. November 16, 2016. Boston, MA.
- Saleh MN, Sakr BJ, Witherby SM, Olszewski AJ, Sikov WM. Breast cancer recurrence in older patients with clinically node-negative T1-T2 tumors managed without sentinel node biopsy (SNB) and without adjuvant radiation therapy. 21st Annual Research Forum. Warren Alpert Medical School Department of Medicine. June 29, 2015. Providence, RI
- Shrestha R, Castillo JJ, Olszewski AJ. "Chemotherapy or Combined Modality Therapy for Early-Stage Hodgkin Lymphoma: A Comparative, Population-Based Study". 20th Annual Research Forum. Warren Alpert Medical School Department of Medicine. June 12, 2014. Providence, RI
- Ali S, Olszewski AJ. "Nodular Lymphocyte-Predominant and Classical Hodgkin Lymphoma Subtypes: Differences in Incidence, Survival, and Rates of Secondary Malignancy" Public Health Research Day at Brown University, April 18, 2013.

Cook N, Olszewski AJ. “Nodular Lymphocyte Predominant Hodgkin Lymphoma”. New England Lymphoma Rounds. Lymphoma Research Foundation. November 7, 2012. Providence, RI.

“Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer”. 18th Annual Research Forum. Warren Alpert Medical School Department of Medicine. June 18, 2012. Providence, RI

“The Ever Changing Follicular Lymphoma”. New England Lymphoma Rounds. Lymphoma Research Foundation. November 9, 2011. Providence, RI.

“Paroxysmal Nocturnal Hemoglobinuria Presenting as a Ventricular Mass – A Late Complication Of Prior Aplastic Anemia and Thymoma”. Migdady, Y., Olszewski, AJ. Kenney Research Day, Memorial Hospital of Rhode Island. March 25, 2011

Voluntary activities

Guest editor:

- eLife 2021
- Ad hoc reviewer (selected publications only):
- New England Journal of Medicine 2018
- Journal of Clinical Oncology 2015-2023
- Journal of Oncology Practice 2018-2021
- Clinical Cancer Research 2017-2021
- Journal of the National Cancer Institute 2020
- Blood 2016-2023
- Blood Advances 2020-2023
- Nature Communications 2020
- Annals of Oncology 2012-2017
- British Journal of Haematology 2013-2024
- American Journal of Hematology 2020
- Hematology (ASH Educational Book) 2020
- haematologica 2023
- eJHaem 2024
- Oncologist 2023
- Blood Cancer Journal 2023
- Cancer Epidemiology Biomarkers & Prevention 2015-2020
- Leukemia & Lymphoma 2015-2024
- Clinical Lymphoma, Myeloma and Leukemia 2020
- JCO Clinical Cancer Informatics 2020
- International Journal of Cancer 2013-2023
- International Journal of Radiation Oncology, Biology & Physics 2015-2019
- AIDS 2018-2023
- Journal of Translational Medicine 2018
- Hematological Oncology 2015
- Lancet Haematology 2015
- CA: A Cancer Journal for Clinicians 2015
- Mediterranean Journal of Hematology and Infectious Diseases 2017
- PLoS ONE 2017
- European Journal of Haematology 2017
- Mayo Clinic Proceedings 2017
- Cancer 2017
- Acta Haematologica 2020
- Clinical and Translational Medicine 2020
- European Journal of Hematology 2020-2023
- Expert Opinion On Emerging Drugs 2020
- Expert Review of Anticancer Therapy 2020
- JNCI Cancer Spectrum 2020
- AIDS Malignancy Consortium Concept Review Committee, external advisor 2024
- Lymphoma Research Foundation, New England Lymphoma Rounds Steering Committee, member 2017
- Health Policy and Health Services grant peer review committee, American Cancer Society

Ad hoc member	2015-2017
Standing member	2018-2022
Chair	2023-2024
• Leukemia & Lymphoma Society Translational Research Program (TRP) Grant Review	2024, 2025
• Leukemia & Lymphoma Society Equity in Access Research Program Grant Review	2023
• NIH NCI Infections and Immunoepidemiology Branch Review committee, member	2023
• American Society of Hematology, Basic/Translational Science Scholar Award Study Section Grant Panel	2019-2024
• American Society of Clinical Oncology Workforce Advisory Group, member	2017-2019
• American Society of Clinical Oncology Taxonomy Task Force, member	2016
• American Society of Clinical Oncology End Of Life Measures Panel, member	2023-2024
• Chair, Cancer Prevention, Genetics and Epidemiology Poster Discussion Session ASCO 2016 Annual Meeting, Chicago, IL. June 2016	2016
• Co-chair, Clinical Science Symposium “A Tale of Two Genomes: Interpreting Somatic and Germ-Line Sequencing Results Together” ASCO 2015 Annual Meeting, Chicago, IL. May 2015	2015
• Co-chair, Cancer Prevention/Epidemiology Oral Abstract Session ASCO 2015 Annual Meeting, Chicago, IL. May 2015	2015
• Chair, Clinical Science Symposium “Next-Generation Sequencing Panels for Cancer Risk Assessment”. ASCO 2014 Annual Meeting, Chicago, IL. May 2014	2014
• Memorial Hospital Wellness Night at McCoy Paw Sox Stadium, Community health awareness counselling and screening	2011-2015
• Rhode Island State House Testimony Regarding Bill H-5158 American Cancer Society – advocacy regarding tobacco control bill	05/2011

Professional affiliations and leadership functions

American Society of Clinical Oncology, member	
American Society of Hematology, member	
Alpha Omega Alpha Honor Medical Society, member	
Chair, Head and Neck Committee	2015 – 2016
Co-chair, Humanities and Outcomes Committee	2016 – present
Brown University Oncology Group (BrUOG)	
American Society of Clinical Oncology/American Board of Internal Medicine Hematologic Malignancies Test Materials Development Subcommittee	2018 – present
Brown University Oncology Group (BrUOG) Member, Data Safety Monitoring Board	2012 – present
American Society of Clinical Oncology, Scientific Program Committee Member, Cancer Prevention/Epidemiology Track Track leader	2013 – 2016 2015 – 2016
American Society of Clinical Oncology, Cancer Education Program Member, Cancer Prevention/Epidemiology Track	2015 – 2016
Chair, Cancer Committee, Memorial Hospital of Rhode Island	2013 – 2016
Member, Institutional Review Board, MHRI	2011 – 2016
Member, Pharmacy and Therapeutics Committee, MHRI	2011 – 2016
Chair, Institutional Review Board, Kent Hospital, Warwick, RI	2007 – 2010
Member, Breast Health Center Leadership Group, Kent Hospital	2009 – 2010

Honors and awards

Academic Proficiency Award, years 2 through 6 The Medical University of Warsaw, Poland	1994 – 1999
W.I.S.E. (Worldwide Institute Supporting Exchange) Scholarship, Worcester, MA	1999
Award for Outstanding Excellence in Primary Care St. Luke's-Roosevelt Hospital Center, New York	2003
Chief Fellow Appointment St. Luke's-Roosevelt Hospital Center, New York	2005
Teaching Achievement Award for Outstanding Teaching Internal Medicine Residency Program, Memorial Hospital of Rhode Island, Alpert Medical School of Brown University	2014
American Society of Hematology 2015 Scholar Award (Clinical Junior Faculty)	2015
2015 Beckwith Family Teaching Award for outstanding teaching Alpert Medical School of Brown University	2015
Dean's Excellence in Teaching Award Alpert Medical School of Brown University	2015
American Cancer Society Research Scholar Award	2015
Teaching Achievement Award for Outstanding Teaching Internal Medicine Residency Program, Memorial Hospital of Rhode Island, Alpert Medical School of Brown University	2016
Excellence in Teaching Award Hematology-Oncology Fellowship, Alpert Medical School of Brown University	2019

Teaching

Practice-Based Learning Warren Alpert Medical School of Brown University	2011 – 2016
Clinical Teaching Rounds Memorial Hospital of Rhode Island	2011 – 2013
Career Mentorship, Medical Residents PGY1-PGY3 Memorial Hospital of Rhode Island	2010 – present
Research Mentorship, Brown University Medical Students	2012 – present
Internal Medicine Conference Lectures	2011 – present
BIOL3672: IMS-IV: Integrated Hematology Course, Faculty	2017 – 2020
European School of Oncology Certificate of Competence in Lymphoma - sixth cohort (CCL6) Burkitt lymphoma module	2023 – 2024